>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @
M.(AJ4;KJ*@'.0NF$&SC5RTZ6:L'#(BB).\SSSCL)CV1K>%%:R15N'"T_1S()+UN>)1*Q"(R5X/"W%F,1QU8)./[=B[;*
M=]K ]\<']=OBX^%CYCP38Q6_1*%97;;Z+1**!<]C\Z0VW\3^@[I6+U!Q5OR2
MS>[9L[,6"?+,J&0?# 1))'?__&W?$.\#Z)$ M@]@GP+HL3?X^P"_^- =6?%9
MU]SPX856&Z+MTZ!F#XJV*:+A:R)INW%F--R-(,X,QVHM-)E"CY$VR59Y&KG0@[(C(@=TJ:549N9"C"C_$= "JIV('JBJ&",Y&>$M\[(S3/C(9Q]P\B>59*GA629T+X^'4:S\B%-V2HMN,XC'GV@@=;\F32)4V+B)09->)[$,K*3!1KK
MGB?.WL-UQL\3:.3*OD0'%G_ZX":)/I2DDL.]2(L#YK]R@^V*OT
M0'%??XY@;!*U()3],O^5S$20:V@M)U9-AE!) HXX,RIX/2$IUV3-XUR0G[U3
M#YPDA8JMJ&>QRS8, UJ!0.(AP)X@15CF -?K6#M
MCP+A,K5 E=TSW*T/4_*#(]OQ>E_:Z
MD #6+JK*^QENVR-8JH3%R._".<)K
MI&!=Y_6AXA^@9)6_^[@;'U+.^T[$EN5:(JU$B97DY'HLXH3D1%ZRDA?JR9CPG4KWRS5B4G))5
MY91G8^1YX3@G:3&:SZK?GOA\QK8R2POZQ('8YCGA;SBN
MO##V5;_-_>3=T>&FAO2=!\UW4=5/#S4_2WGM)" "$&EN'1$Q$U$
M7$7TAR(2D0"5&Q#K!_IMF^Y(IIJPYJH.%5:A](+;S?T >W VWG538EIA"'V_
ML3K0Z34YVI$=U3(?$AD'2?H- \1A'V1IA4*$+)K#!J-@5/C
M$Z ?E=52U!1Y97)A'*U-+H#9Y,=6&1'84^UQ6@*!S(;-JI#I^IG)DEV
M@L#0:#N8A)-)3Z%IA8-@XMDE1HW$Z$AB%0>X?*L2JN=HJ4?_#!14VI1&AH8)
M#GHZ31N(.D8',B>-S(E3YF,UU,,9G%AR$_83:!I-_7! V+01-CUAB(>%38TV
M0^Q-^TO&M/)#-#2TT&LKNG=23QRU&0[UN"SE$Q\3Q+6UKA54<,C,^G?I]=:85A*$7#BALP0"/
MD&$_+J4JO'H'P]8@8\6FKL$K^F)=>ON8!U4B#/ISW&+E3^! ]84M(J";$8\'
MI;8SGZQ*30+@T"BX%BOD14.CWX("NDEQ6'./*;54?3_0^XE#J1:SB=\IT(=:
M6SQ -Q\^'0SZ&2PRC91X/4EFR:^'PP4.]C2 KIQ4<^#8UFU$" *
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MA3%U=+0J/4XKB\EY$ TNLA97R(VK.JTGI]0DDC6E-KQ-\=!\;K]O_A [O.+_L[FY./.+B%!W;#8Y_M?W\DVYUK*_QKL]U69.RNR#^=;=^X
M_S*R[3*I98\[=Z3Z@OHOPC=I(=3N>ZU\O(M(#16O[WSK%\G*ZMKTA4G)\NHQ
MH42E1QNH[VO&Y/N+OHEM;M[G_P%02P,$% @ .(AJ40M141Q5 P R0P
M !@ !X;"]W;W)KF 1K 5/;;-I^^K,-2QY( FD3*;%A_N/?#..,
M,]XP_B(2 (E^9&DN)E8B9?'!MD640$;$#2L@5W=6C&=$JBE?VZ+@0&(CRE+;
M=1S?S@C-K>G87%ORZ9B5,J4Y+#D29981_O,>4K:96-AZN_"5KA.I+]C3<4'6
M$(+\5BRYFMF-EYAFD O*6
MHXD@A4AJ%T1]O<(,TE1[4AS?:Z=6LZ86[H[?O/]M@E?!/!,!,Y;^2V.93*Q;
M"\6P(F4JO[+-1Z@#,H 12X7Y1)O*-AA9*"J%9%DM5@09S:MO\J-.Q(X #T\(
MW%K@]A4,:L' !%J1F;#F1)+IF+,-XMI:>=,#DQNC5M'07#_&4')UERJ=G,X>
M'^:+AW Q1VH4/G[^-+][4I/[N\]W#[,%"C\N%D\ANEH2#KE,0-*(I-?H+_0M
MG*.K=]?H':(Y>DI8*4@>B[$M%9/V;$?U^O?5^NZ)]4,H;M# >8]/@L?VZ&U>7U1[^H,$?7(1/2IDP
M3G^I"YK?,(NCT)5?;P=GH%\'T%U6>]##!GIX%GK&LDQMZ-]/^+!7PKNL]MB]
MAMWKS]X_VUXKC]CW/4>_#JB/6 [P@>4>N=^0^_W)J1!E-[7?8@D& ?8#_Q"Z
M;>@%(_5VO>/,0<,<]&=6/4E(]:-#\W47>- 7O&UX'ORV ;\]"QX"IR#0(]IN
MT% '<>87:]2X'EVTY?L]RE&[K%PO\ [2T66U!XR=;:);Z(/*7?2QH3-MT\&5=IU\)XG8S&0[=T6%"VE:GDK'M-_A\P_F3^AOV@FY;G8+>-AI\
MOM/\0>EYK9K2S*W2:YL=0ML[YTQ]R/]"^)KF J6P4AKG)E N>'5NKB:2%>;H
M^;?R_1_4$L#!!0 ( #B(:E%W"KYG
MZ04 #,8 8 >&PO=V]R:W-H965T&ULI5G;;N,V$/T5
MPNA#%MC$(G6S@L1 8GO; +M)$&?;AZ(/LD3;ZDJB*U+Q;K^^HXLEFQK):?L2
MZW(XY#D<#H^8F[W(OLDMYXI\3^)4WHZV2NVNQV,9;'GBRRNQXRF\68LL\17<
M9INQW&7<#\M&23QFAN&,$S]*1].;\MES-KT1N8JCE#]G1.9)XF<_[GDL]K(DV6U4\&$]O=OZ&+[GZNGO.X&[<1 FCA*O%\PL&I2(
M7R.^ET?7I*"R$N);,0WHZ,8D0\YH$J0OCP\\9G/(Z+2#".O^J@HZ;/HN'Q
M]2'ZIY(\D%GYDL]$_%L4JNWM:#(B(5_[>:Q>Q/X77A.RBWB!B&7YE^QKK#$B
M02Z52.K&,((D2JM?_WLMQ%$#B(,W8'4#IC>P>AJ8=0/SO3U8=0/KO3W8=8.2
M^KCB7@HW]Y4_O+E[?0 N21?EW-R\=,'(K=^QB6)
M4O*Z%;GTTU!^)#^=W-^,%0RQZ&@H9CDB\B55M)%FG(0Z3]?+B]
M-]!^#-(T^K"#/O=L,."2[ZZ(:7PDS& &,I[9NYM3#Z/S_WI?_.?>3\0PFV0Q
MRWAF3[R'-! ))TOE*P[%0I'?[U929;#8_QB(;C71K3*ZU1/]($,H<$
M,(M%7*A%;SS-.9I*53BG#%<4Q+#ZCI-/&=035?N.1^%FS+P"&H&(M=
M,6>8D%4D^XB?XWF6IF47Y-K>1-.R"Z*.9;N:G@C*H\S!!74;PNX@X9]Y"HK&
M)5\_A%(9%:E9;$,89;C.^ETKR^5LXCY6<2BBW"/TNB$HM=0] 8I/JDMSXAH%LL0
M2>\LR;.(>1=A@>?2> Z%.6%)C78;-@9YO@H%N2L&B@*ZF1K=M**&I27?#(,!
M*ZIQ1V F\UPMX1<8S+(G/;E,CYP(':[_0DJRSD1RD$&D.&G:Z?\298W@/)V"Z$3? C"0<51;3WFV%H(.>XB&9RT?2M3"\J=#
M%4$Q2R\7&,JBGDX604UZR;8.@MJ#9.\2D:GH[W*E$+&&77ZE2!C)0.3@S8K:
M$4F9^VG JW*"BF$C8IA4%^,]J#F&,CVJBW$&=2I&:W?HL-^!ST;X*$QAXH.M
MGVXXV! (E@((RNUD *R#*^'=&MYZ+#G*4LF3#Y,
MNA1Q?DB$Q/]39)'Z<2GV*0^)S%FZUJZ#D.1
M3D5H31 ==D'5UIF>5-%Z^7\D*4<=+^U:E4M&79TW@C)-6Z>.H"Q++XL+#.88
M?>Q;?T2'#=(C5Z1(GP_=]8U,7K6GX?,ST,6"*3GRY&U3HD-
M.Z7#G*/$:.=C%9U4%(=,*H;#)A7%P:3VV$+6VB/&!LG>^S(*JJ_8"$HN5I%+F DA_"[/M9];)\BI;_NM/)\7"-JXX+Z(%U1$)AME[]
M>F!]^="Z.S;L[I;545PN01Q0(/#C((\;6[#ZEP)6!WNX:EW7YIH=2SU#8+;K
MZ9O!'($YGN?HA;,GFFZ?QD>'H G/-N7ILR2E&:J.N)JGS0GW77FNJSV_I]66
M^R'/"@"\7PNA#C=%!\W_":;_ %!+ P04 " XB&I11KDWT08$ ^#@
M& 'AL+W=O4EB)@>-4*G-M67)10@)E5=\ PR_K+A(J,*N6%MR(X N4Z,DMES;
M;EL)C5ACV$_''L6PS[-Q^8_^4$OS+7@LTU^RS[%V@RRV4O$D-\89)!'+_NE++L21 ?*8
M#=SZ\'/S?PW^NAE1NDH5M9[*EP8ZKHL"_XG@B-1C;=2-5/
MK5&OB.E$F2J!7R.T4\/1Y&$$R#,<'6=/+U;GPSP\YTAG_WP<-L2B:?\=/]
MXU/P!7%WWP+R=3*=DB9YGH[)QP^?R <2,3(+^592MI1]2^&L-+>UR&=PF\W
MO3 #C]QSID)) K:$I<%^7&W?J["W4(U"$O=-DENWDG *FROBV7\1UW9MPWQ&
M[S9W>J9P_LQ[\+^]GXCA%?GAI7S>)3Y%%6!A4(2OR(@G6(U"729V0.[8@B=
MOM_,I1*XX7]4N/,+=W[JSK_@[@%+8\RE)'/ (@B$<73"E. Q(M>8:0H$2&7*
MLHRXG1+K\K@;-AW';7M]:W>\>":8;?N=4]C8 /,ZOM\[A04FF-/U#FPG*K0*
M%5J5HD]4"((L3M2.,K4_:G4^75=(W2Z6Y)Y%J:P$#3ZMAF=3M%X)W*P)\9GJAQ
M] N69)5K "^+D+(U9+F'\:>)IA> LE<\B&+*%F 2HE,KQ#FBZ7BM4AZ-:WD"
M$T_;N2!%MY"B6[O=M@W_>LBX'A(8(*T+4K@'*=P_E6(TNS.&
M[9K/VK/833A35AAPQJPPX3 KW)(4UM%]. &Q3A\B$K?WEJGLZE.,%H^=F_2*
M7QJ_=:Y'CF%\K!]'Z?W[0)^]K.ZI6$=,DAA6Z,J^ZN"2B>RQDG44WZ2W\3E7
M>+=/FR$^\$!H 'Y?<:[>.MI!\60<_@=02P,$% @ .(AJ4:\>,9=W"@
M?3\ !@ !X;"]W;W)KV
MF8DCXI-DQ_:,9=FQXM9V+:>[.SO[P$B4Q48279**V_[Z!25:$'$O0-'.)B^)
M9!T !\#%/0< >?24Y9^+69*4WI^+^;(X/IB5Y>-/O5XQGB6+N'B7/29+]M99(NDF619DLO
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MJK[JPSI.U^559*7+:DF-RES]FJIRY*U^N#F[NKSY>7!^-_J'=_[KQ^']O[U#[^-H
MX/WXPQNOF,5Y4GCITKN?9:LB7DZ*M]X/C>]'O5+QKEKOC6N._0U':N%XGY7Q
M'"EVYBYVMEJLYG&U8KWSZ50MX;?>;9*GV<3+IM[I)'NLUO1;]>EW-= J2Y1(
M$P-W$[=J_2=YGDR\49F-/R,5G+=PS!8+E5ALI2_O_2NK[&.%ZV-#X>;QI1(WE3SI+<4P.C)&)6Y6[5[G YSA8)4N]P
M_WH'R30=IQBY#YTK^1I#397OSRH$2@3M;*,BGIJM6^7/-TN
M>;JNF5MJ[BK-PW7ERJ3H[?>8R\]:A/0FQ1;.H7
MZ_HKS?YR0MA1[\MNV$.("*)0;E$-YFS+G'5DO@?;_J9.N4N%1BQJ$CZ#*$(B
MV00-(,@W^HTT%C8A%Q!":<1]*IJX]Q!WAEPAI)@Q*0Z0>2ID,S"'X@-1&
M?6-BKY#:1" $/K%\.[%\78Q9)E:M;^4'"Q6):C;7G]Y4FK%.B[-L/DGR0HG-
M'ZNT_,O[SYU:$I[R4T]Q/OFO8SV(;>/"&56;>@\K8S;Q5)Y1;K6(JP6,!9.
MH4^%,2T7+: &2[EE*9TLKY6]GF<%*I\2M'=(_)!P(Q!:80UBP998\++AVTTK
MF#(&D(YEC,(ME=!)92,=XX9TI#;IZ(>@?6-!7+H0#8+1EF#D'JOEQ)%W?XGS
M;2:+L+P;M>=="%%Y-[#0)KYVB7X7XGN0[=<(4>W&"/OVJDVT9R#\Q8I8%VUTF9&044N?M5<@;K/036((= *'U+=PT$Z
MN*V 6T5&R:-:9;Y=10CT 3 O0(Q+1[17("UF >A(&]T^@3Z!2A(1<[D'["-*>
MUZDV>]3_]GF=:N=#W:(J+NQYJ_#>G?(30?; FH2U9K(W)KXRLT)V^-N <$XX).AUQXO" > ,0+
MQ%2'7#;VVBHPMU5H/>3"0P:Y'5!3Z)LA(]I#!D)@R,#65,A$))1FR$ @B!?L
M-$-M6%N\S(LBM5ZGK-IE8JKF_NB:OJM
MMU3:H?Z8/@/&65$6;1<@#'$00D:V/*85G[FW_!UIHD&*[/D%#T $AO#\49H1
MB%8E;'*MC05S&XNS;/E%S7=UT:2Z-$KR-"F\?WF/VT+=3.
M^S^4;I]#U:64A8:9']0PE\XAD,#<$V"M,2)"8E1VB0!-G4,@2N?"(.#&"<05
MAK3K'-?.@G=U%EU]$4='!M_=%7!L.[C8BC"OM7%\[E GD0P9/(#X7
M4+&Y#(EQ?3&H8:[UB4! /D=:HTQ$@7GB\,AEJ_8+[* ":K]H/Q9!(#!6D-90[4>
M9BY'(!;MQY#V7"ZTU1+?XUG(G8M;H9$ +P!FX4+EHA34[I8V"/2VKOJP^%>DDC7.<.F(;0C\RF2,7\23BD9DQL(4VD7(/2XET >2$5$V[YC=F"8C+;;R-;-N-)*
M1&E-2X9@')9,:J6576\?VNCV)90@(4-I>(.!;)=9! )D%FE-6;)0@-L'!&CF
M702B+)E/H,PZ*VL.M998^1TD5FJ)E5]18B4BGA04>42*'YR A08PK(6G=
ME)U>5MAGCRCAXW+8'A&!@80$(3 A00R^1T2 ($HAQ+)'=)+?#'5OYWWF^^E-GC^A7=3UE99HOUQUD2JSQ4 =3OTRPK
MG[]4;_UNW[@_^1]02P,$% @ .(AJ4;GX +B7!@ *!@ !@ !X;"]W
M;W)K)4/$Y5+1F,S*$TFQ/.FDY3R;'1Z
M;+[=R=-C418)S]B=1*I,4RI?SEDBGDY&>/3ZX0=_V!;ZP^3T.*;,6*G_F=
MA+=)XR7F*P/ CWL
MJ0>0[H"@9X!?#_!-H!4R$]8%+>CIL11/2&IK\*8?3&[,:(B&9WH95X6$7SF,
M*TZ7MS<7ES>KRPL$3ZO;;]<79_?PLKJ'/]\O;^Y7Z/8*+<]67]'5M]O?*S1&
M/U<7Z..'3^@#XAFZWXI2T2Q6QY,"T&B?DZB>^;R:F?3,O$#?159L%;K,8A:_
M'3^!*)I0R&LHYV30X8KE7Y#O?4;$(YX#S_+=P_%B ([?9-8W_OP>?[O(S%4P8 5+E6/.9 ;ZYT5C.$>WGR9[.@DTS;R'/G<=8@GPTBO_Q;
M:H":NF(4B13X7%&-WP5Q9D/TYV$'HL-H@;$;Y;Q!.1]$><% 5").*ZK.8D13
M(0O^7R_2N0-$MS!MFP 3-\Y%@W,QB/-.BATWD@2;"5T7-.$T0[_.[G6!,KZC
MZX0I$T#,-=D8$])!Y+#"
MLYY=CO?T! _N\^669@^0L[>;5RE65'F$!*]Y(_:L]W5=>D*ODY?
M]")\!J:.9,F<,>PMOC.0P*[;V=SO\H#++ BF\YY06H7"X4%I/:@^3MRA#=[4#SW]UKX%9L\+#:W)4RVE*]B*".:@L
ZM,>%B:FFK\6)?C)Y1KM8)F&:U?:NSOJ$U;>,:+J1V%;8;G
M\X7OCH*T&D6\PU?"
M_ PZ)>5>Y'J:_<##!?;FG?PXS'I6F+3*18:5ZPZ@1CRGB>;.JC/6+2E;.[L,
M8DO.&,JLNY 'S=Z";96)'%*F_7S#N31Z!'XT_1U[9C+BREU_Q)8=W\)LV_3A
M;76)#.M2!R]-JMT/'7,*D"O\)9P\)6)IGH@7QNJ/>4UY*$^HLU4EMOQTNWZ'
M24]#35IU(L/JM-1<8)H#W:I2H+ M&Z=4/D*E,W,H:,I_H-IM!;(6PR%204^;
M0%J%(L,'KH;-]CFL9;;-09JH\=OGJ3#$0;>U=9C!)@AZVC/2RB$Y&
M6-AS9!I=! T"L$O=]$)EF2!UQV,>],+LH/9Z%(;8^F2*N19%@CEWU887^@
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M!!0 ( #B(:E$\#X0-R!T M8 8 >&PO=V]R:W-H965T&ULS5SI<]3(DO]7%"R["Q%R8[?-/4.$,3"/MW/PQL!LQ,9^J):JNPO4
MJAZ59-/SU^\O,^M2'\;,FWBQ7Z MU9&9E7=FZ;MKVWUV2ZW[XLNJ:=WW=Y9]
MOW[VX(&KEGJEW,2N=8LW<]NM5(\_N\4#M^ZTJGG2JGDP/3Y^]&"E3'OGQ7?\
M[%WWXCL[](UI];NN<,-JI;K-2]W8Z^_OG-P)#WXUBV5/#QZ\^&ZM%OI2]Q_6
M[SK\]2"N4IN5;IVQ;='I^?=WSD^>O3RC\3S@H]'7+OM=$"8S:S_3'V_K[^\<
M$T"ZT55/*RC\=Z4O=-/00@#C=[_FG;@E37*GJ/5<#4W_J[W^F_;X/*3U*MLX_K>XEK&/L6,UN-ZN_&3\O3*M_*^^>#ID
M$YX<'Y@P]1.F#+=LQ%"^4KUZ\5UGKXN.1F,U^L&H\FP 9UHZE,N^PUN#>?V+
M5]I5G5DSA>R\>#DX#'"N4&U=7,I!T?-+LVC-W%2J[8OSJK)#VYMV4;RSC:F,
M=M\]Z $+K?B@\ON^E'VG!_9]6OQDVW[IBM=MK>OQ_ ? (2(R#8B\G-ZXX*5>
M3XK3X[*8'D^/;UCO-!+FE-<[/;#>'BR+_SF?N;X#(_WO#1N(.S?SGE
M;]R7I/R96ZM*?W\'8NQT=Z7OO#B9%'\-/,7%^[?%2V/?+15DIKBPW7I2%KU=
MZ'ZI.S!WORQ,[Z $9L[4!HN6A6J<)0'77:=KC"W U"RU5[K9%*8M^J5QQ3\&
MU?6ZPY-?]=IV?0$X23"+D^.C?Q3*%?_Q;T^FT^/GU[KD7R?/PY/!;3^Q0Q
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M:HZS2D# 6:DWLC%?$BR4O8%C;?()" >0X
ML'9A>35@Z,AF$R\3/F_ /#SA53Z#F2G[T>NA +#83\1<\\8EYKVQSQ1)4Z"_P!L%Y Y@#QT%:O(T 6*@+HI0*;
MTOMW9:7E3;>]:&7H$0M$.KAII).#K&; *7@ /G!Z#0Y=8:J8U1+S3("E<16MJM)20C/JV3-
MUN"^RJP;$%RT7 ,NQGO:HH['/[F<,&2FA5TRJT-8 A>G^:8%APUL$/*&O8K
M1@U3STDG@0-.CHD8OXHDT;J71__-FH"6)2GWU@,'"&81_>*&:GD *N#7##4)
M3-- F7R"IRGZ]![4+DY/!*YM-F*1,(U.F#0:\UF:<+_@"; ?H$P+'>0<>0K"
M@',%4[/.F0"KD<9,0*VM&,<":ISA9=7I#977)K0E%H%>%*ZLE ->B"?$)O(T
M##2V)FG8F?)GN0<\WMH^(F58D9/-8-4%3&C1L G;(1*7F4A)Q7SM=P;ZT$XL
M5R3D3!S(F4@R"1'4%ZG_P$F"S*2X$/GYM3U @SDQKFJL&TCUR2DQD'RV
MS*B)T([4E)SQ35*PA]_W"P8;'18JNS(]C5L/G1O(+_0&HAMHG*<32\LE<1".
M6\LYOOY2+56[@"F!;V"L+M@BP-_OT1(8-K11L/A$%ZGYI!S@N,SH=
MQ5B"1S\-K02"C"8QX8VKAJ/C,Q,>>05&$!8Y*46OY)2F%<_;=L RN[+\7]BD
MT9DB 'KT_B?5@7=/3H7EQ 0"UAI1+WDPD"SXU36C-E,-GY+$ZF"V77"BFH,T
M@D5K<*V,'A[4]^Z<#^/L P8X2O&^)Y#")$O-2"B-L$..0^&$X(A'6
MZP0H?GC=0GC1WHY0(* 1EO2V8T_DD)R1YL,6Y'QB.5X )IAU:%4-*^\6!9.^
MPHPE93P 'O 2W@:IP,9N>TX-[[XRT/):@86P\MV3Z>2X6)FF83D2Z[G-)$\"
MC\$U%7& L\I'+30A,L!;9.;M+9Q#K.,TD4W^ L+5YZ5M*%Z@@.CD\?."CKW?
MB -T@'DSHI %$!6- >4>I%D%)!4_@1<1N063+^*Z>YV* P#L/9_ W;U?9/#P
M40S+E"=W&,@VFR-[W1(:6=1*@WXT33('$5)X^X=J4^@8WZ?;N<@[B#HXA:7-\2)K^:,(GDU0V[L3"(*>-W
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M?&@PX$K@)+KY0)QR$Z9/&X^@+[V".Z+LKP]?P3%\OMAZKB4#O:W)@F\:?
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ML6(-O,RG?-25CIH8!BTI@\AT(Y!D.79T8,@)BVUPF!TK@W0(Q$FQUI4PC*7>XPJ4XQ&2((.713B'0[?HC
M2-,J-R/BN-Q]^'AR%L(!'PWLPW(+;*XD##%KDPEE3/ )3W%R:$8*8DX$T1+W
MKR@XI?EVUIB%\EX5:UD6&LC\X-,[%OAZ!S@%!.2;64^8H0-[_2X9,H(>\)YP
M-1L=I4D5Z[(?B0%0PBN)E5L8X6'=IWE)$_,M1U8.S^%$M2C0J;B@[R[S!R)Y#,X30P[NZ\KS6
ME(KF7#H5;N#?K6W[+-?1,1N>;9^L.DR(YUEQ"GS%)R8Q,M.040!N6,L!?T].
MCWL^JF9(J6*\G2P>(!\XZZL:YNB<9&LJ*Y/*E;*C) 2&%CY*2R%AT)UDO>.<
M?!_6AI1^A"[YS#K5,PFY.XK+/)3_M,-B"?F ;%:TU+J#.H$DB(,;9+U=0$>'
M4MS2K+U7"_:*4?LG\%%?D!M!7G])(4!,Y$8'BBSIK,]6I2TIG*,,.!L>#)FI
M]G.!E3M['8;XM*A7-BF$:A>3XF_VFA1ZEL6)'G\[L&:C[0=XH1V7M1RB9EF$
M?'Q QPF,3+MR M^1OJAVG&OB1LZ#^&NB/9T&120C
M'5EF6U/\H*ZL5'A(B?,"Z3T%;4TS*=[.=V60696.F$-I0H ]>?H8IJU'*L)
MXY,#X _]Q2?Y\XP.PRS6F+>])J6#*!KCA08C4?!L!6^S9:5!J8\M[1.J@7N]
M0@CQC$X1H5 =[9!/H>=B6"/.A'YR%5%\IG!\Y,.&N!R,LN(*LL]1$@3!EQ/'
M)E,^4 B+3JV([\9[<%I.?(-;N3 S3DOSP4&>>^X*\3XBTTDJGT>P7HV9&S)*
M(*^%+#=;UC7PG7@"4I'!<+$(T[4)8"FOA3R;8>4N*N5');[;5IK'CEJTHT/)BBL-2DK.L?83;6"5*P>MR>#.(SB70
MYTF76 K"6GRD7,T&7G'[F9."EQ]?EH&OM54"+
MO7G)Z$0@X346LXZ+#ER=W_C"4#XFYPD54T2@!O5<:,\FH6:3PO1,IW$ER.CJ8I,T0+5HHZ9+*:%_QJ,J*UY*1)W^F:
M7;"T.&0\'BZGTS05E'1MQ'4-40_4)!&72J&Z^-&V"XG>7I$*G5&++#LDS9[4=E_-2_1Y'Q:=8)D'T](Q)1/^# Q#"$=PIK-I+C@Z)3^
M+5YO1:>7*3I]FT6GAP)NZ;W9+FJ*Y'Q[#.S;&"A4G/OI\@*=Y)9S>JE*S[
M@GJ!VJ@#N=DF]Z)\0-.M+3LS;._26Z'!;>&2&(/"+DI8]-(B05$L>.)-_"V6
M:\Y.IT3/Y*M7/EEVG"$=.-(,]>^N1R"-B5=& <@6@='"3(
M.ERTC:#$A5:0\P^?D37M>B"%Z 0YO^B(6N]C=E,:.QI2XTY2ZE^97(H._9%F
M%"?D%*62[F))!2U?(^.[%(F7\'C&0=E).#J
M,OL-5 6W'-6*C ]6J;TJ_FT[8;
MJKK-N0/:>^7VNLT+>L&OO$H0!(_79>W9GX9Z(4Y-%PHR;$E^BT+J+5>47>H?
MVU&2"3M.!C?6^1:.*JLD>G^-?2IN$R4K1@9$!180-5-S,D,< (9$-F9;*V%_
MTKH#;S3K[&<\9[[QQ$002TVK>\Y+2,X+Q[X&V]1_QGZ *18^B0#6#RH@\.4W
MV3 QWG/XV9SD**256N[!D,8KB7S\96A$%Z=NOAFW
M:[+E8Y\Z(3[$5I=L=M+<]]CEM8/#7'?_V3YZ[#8I75C'''F^ NR\"S_YH:-D
M_8=62G%X^@,<#+?[^$=)G[_G;I10#*[% 'UD^+9?L76^"Y">XE\ONZ-?\N;D
MR9-H$!(3/J-[*ML"<796/GTZC2N$__WCZ9/RZ'02V/UKJ=M[&][O;_T_+A
M=,I7*_;Z(\7)M#PY?@)F#1/HP;Z=J>X6#Q^79TRJTQ'YZ/')
ME!Z?EH\>/2K>4DNY:OUIG-V!A_/WY>BB )87.(R%-WNWM @H5Y8:O62,$&J
M8'$[DF-("M;,6@RS(JKBVP6L@WA0A8>F9VT4HG-VGWR[3\A642:14F^U3HB1
M?R+9_#ZL=L_#*^(:JZ8>'[)(I*
M S(UY\DIXRI.740^7(*(_2&^W22TB10M=0+X"UB<^_'DWFUOL0TA\V5,M2/?WMUTZ\&S*]]P]FTQ3)Z2$]F;LW/["WD:J%<<*
M2^#+V_2(;^5X?)M=[$CE-KM'$U_<"\U09>!G=B:X)6^0;;/D.J$;DZ[L:0=E
M=!UO;-51792IAN4C_< >>()()=7*Z5TB?!MHYBEX0R>TR7JZ^BR05&[/KARO
M6JJO<8N_X$$',ZQ)@+PIFI:UA-/N12R+7JV Z@S]9
MA%+#7HFZ7X:\()'>4,D-+._K+(P?' 90ZD=*4Y/+09F=\\N+XLG9M#@*CTNY
MUD;6D?B#T"D^*
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M\2J236JYQAP((==??'M*B^>1B2MVZ#S=$&WKC8
MLCS7Q8[F\KM'%4MH;;&C$U)'%<-R0M5L)A!]&2 7DVW%Z#CY*]<.#\1DT6NB
M%S]\O7#^E^I^;@W=<>G\RW0AP5_#+BA3%3IX=W6Q']S:]NAV$_9N'J9N+RUO
M\Z=EZ!-E)[O\"F%&]I_X;EPYHDL-H9>?*DW?4D?\^#*+N#MPV"
MI&\)=9!=S@%3^T (%N+%-9+[:VY]S+KI\@Y<2O-,"#Q_FT'X6\<R/4[[M>% 'BJ
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M>8^,V8S)D(4A;'-Z3
M)U$\_2:TQ,/3+&/BG_^Y;Q_LTQ(G3_?O>O)D\O#0KMD73*(-:/?J(;EK^<4+
M#_<
MPO27/'WO=GC#H;9/.<8M"<;M6_HK6Y-GXZ1;]@!0HCLB3M!NPM'$VPROH1Y<
M_WF8F5Z85KXZP_>Y8K*:;E/($:*M.#'W^;)L)I4_(?:C(CC Y.^J
M':A[[R3_7@*/]@S",_:=S_B6>_(LTVWW&[SO_9\BB SU5ECC$#_Y:]@GC[Z5
MFQ"0RFV(472.D]3R@9\5A90)MJQE(G!"Z(6@EGL/-3E47(?/VCU'-U3I>O91
M;X] (G&EM\J+)7O;+IN>?V$F[B3(.D^(Q,#T=!#_1CY0!$Q('QXUUG(7\IWH
METKYC 7]CD>;0X/T;0E.%:3V/W;G5$?5O5'"44R7O99KW40ZN80EU(@-]T=X
M<\1M_=L558Z4AE2$ENE;*+;T_;_X':JT'S<$)M>/:$1?)>&LFO\6A,\)^;P
MIPKBUS9"!5: =?2)%T:/HU-N Z2.0!/ ^6ND=SJ]27I[^9P%@AA%\4T40,,*
M64W=
M:/3I@\N+XNSQ\1'<8[E7&UIUY#,!.M^<]J1SX!IVYGS-M>)@B?I&=V?1%\YZ
M$07?KT^7"+P.J%3D]'\5\YS^L\PC7R[ZAAV/__^PV[Y/@S[(/M"ZTMV"/T/K
MY!MN\JW6^#1^Z?9.'=R13&_[H[9H_]SJS
M?6]7_',)?:,[&H#W]+V>\ =M$+__^^+_ %!+ P04 " XB&I1$"4EHS$#
M #+!@ & 'AL+W=O[ E43SD
MX;%$3PY*_S)[1 MWE9!F&NRMK:_"T.1[K)CIJQHE[91*5\S24N]"4VMDA0=5
M(DRBZ#*L&)?!;.)M:SV;J,8*+G&MP315Q?2?!0IUF 9Q<#3<\-W>.D,XF]1L
MAQNT7^NUIE5XBE+P"J7A2H+&]H%$#>&*NJ#DP,*B[;D=UU.IP!QM$3@*0#
M))YWF\BS7#'+9A.M#J"=-T5S$U^J1Q,Y+MU'V5A-NYQP=O;9[E'#W!BT9A):
MBNCL8=ZA%RTZ>0*=P;62=F_@G2RP>(@/B#;C!N@]IU(,D2J)G
MXJ6G\E(?+WTBW@I+U!H+6"IC30^6K.:6"?X7BQZL-=:,TX3) LZ%@!4WN5"F
MT0@_YEMC-1V>G\_0&9SH##R=P7^J_3PZZ3]DV2Y8N\@5711CJ515 FU J03=
M."YW\)I+LJC&4)WFS160R!:K+6&/2L,*\\X2.TN<@;^>%ZJ\: P><[R$I#>X
MS&A,>^DH@X].2B;AV_P+7= <^2W;"B29)763U_$;>/5BG,3)6QCTTBQZX%Y@
MK0RWC[B.4UA2Y3QG JSF].Y\#8Q&$8R([0V6C2Q<+C"8-YK;/T:U[UGT*1>-(3ZF
M!6S:UNGL&[Z3O"25I(5YGJM&6E? 6@F>K>O6WSUTSO2!P0
M6!(TZH^& >BV=;8+JVK?KK;*4O/STSW];5 [!]HO%0G5+5R"T_]K]@]02P,$
M% @ .(AJ4>4\0:&8 P M0< !D !X;"]W;W)K&ULI55MC^(V$/XKH[2J[B0@+[!EV6618+>GKKK7HJ6]?JCZP4DFP5K'
MSME..?Y]9QS@:/<.5>H'B#V>>>:9Q_9XOC/VQ6T1/7QJE'9WT=;[]B:.7;'%
M1KB1:5'32F5L(SQ-;1V[UJ(H0U"CXBQ)OH\;(76TF ?;VB[FIO-*:EQ;<%W3
M"+M?H3*[NRB-CH9G66\]&^+%O!4U;M#_UJXMS>(32BD;U$X:#1:KNVB9WJPF
M[!\2SOHH0)H<+",X*@SU]XCTHQ$-'X>,",3BDY\'Q\
M1'\7:J=:FW=]%U!"56HE/^V>Q^Q$,]5XQ7&.7"/^QZWTD20=$Y
M;YI#,#%HI.Z_XM-!A[. ZZ\%9(> +/#N$P66#\*+Q=R:'5CV)C0>A%)#-)&3
MFC=EXRVM2HKSBU_\%BT\29%+);U$-X\]P?)B7!P@5CU$]A6(&;PWVF\=_*!+
M+/\9'Q.=$Z?LR&F5703<8#N"<3* +,F2"WCC4XWC@#?^KS7"@W2%,JZS"'\L
M<^",U64SGA"[=VQL@.3TV.0$<-84'+ Z6E"WI#)Z0CO9YA@%HHX=%9RUJ#]]"
M.AA/9_3-!K/9F+=Z:*IA)0IVWX-"VGL+%2*\2=_"=]]<9VEV2T&327)D;W0]
M]&@;,+F2M>!+Z6 \G<",?K\:+Q285W5RXNG5F+Y7@TDR#>@7D@O'>KPNSR*U
M+$>5.!#4"AK345&MV(M<(7@#&T(B2> KWL!+Z!;HV]!WR:E@"PC4=M3,D
M34CV4(DR0H](8(2UL!X>'P?P2%K#]2!(D"6W/QM/55"&>ZK6*%D*WK-W4@M=
M2*IXX\G ^"0X^\)T!$\GI1XP]P$HO3WF7VK=4=PSMH8R$D-N3I FPY_H"-AP
M%/8H++ FY1>48"=1EI+E)QRI^\9.LQ$L@WJOS\N 8*6C[J>(-<*65,X169Q"
M">=D)5D0<]CHXYDYW\9>I%!@.B)6KK"R#6V9$JXZ1Y? \=:4L.E?AT!$UIJP
M"T%@RZ+@/>/SO289"P8=_DNI4%O5V<"B1"^D+UWX^*R5
M-FCK\P=:/D?5<]64]OTK)OQ9_=^P?MO;"UI".NL*+09#2]BL#VCT0_\:8-
MC3DWGMI\&&[I747+#K1>&=+K,.$$IY=Z\3=02P,$% @ .(AJ40WD6[=D
M!@ WQ !D !X;"]W;W)K&ULI5AM;]LV$/XK
MA+%A&^#:JN.^I$@")&V'=D#1H&FW <,^4-+)8DN1*DE9<7_]GJ-D67FQTVU
M8$LF[WCWW-USQYRTUGWQ)5$0UY4V_G12AE"_F,]]5E(E_W
MFOO:DSIY/-G^
M\$&MRL _S,].:KFB*PJ?ZDN'M_F@)5<5&:^L$8Z*T\GYXQ<72]X?-_RNJ/6C
M9\&>I-9^X9>W^>DD88-(4Q98@\37FEZ2UJP(9GSM=4Z&(UEP_+S5_FOT';ZD
MTM-+J_]0>2A/)\\G(J="-CI\L.T;ZOUYPOHRJWW\%&VW=Y%,1-;X8*M>&!94
MRG3?\KK'823P?)_ HA=81+N[@Z*5KV209R?.ML+Q;FCCA^AJE(9QRG!0KH+#
MJH)<.'O]M5%A(SXZ:;R,0/F3>8!B7IYGO9*+3LEBCY)C\6&+@IPR*Q%*
M9YM5B6\2N8*'*FUBRML"Q9;ZS*DZOO>"P8K2ZIP+$B&!ILX^@=0
MFHE7#7$B<, *8Z^%9FV/D8VC WR5$O'6,@LLXT)+%+T
MZ7)?&G)DZP99#E(5JP:R)A",K61.(MV(#'%!5]FB'V'?YNU@"BOOS1$Y#I^)
M\Q!_#&@=+,J9)TU^=-5"6=V[ N6;$+#PE%UY51 5% M#(MO5>%XDR''_3M
MFS0H>$%=B<.7>(9%J1B/37CR5BNV.T=OT='.KA?#(3RW7- YP VBE&L@BS:6
M0QNC;)HJ1<5QIC6AM$Y]BQI'I0-XO S*%YMX[D[ L4'L1)_?S5"[HTRR]99#
M#B<2N.JW!DYV5'4G4C&?UXR( 0 9!@=/6R0>=&$:DP18^B8KNPAY"D$3QH*P
M3=,[-O_D!5V3RY3G@!K UZ):>%]P5FO*D21(4971DV70\0=<97&&O2CE?
M4Z1M1&N_!XHS,_V,"3/28D]86E4*3G$GGW+.ZR;OHMZ;TQO0@M8Y+U$?I4H5
M@U X6PU^0F3_P>S_S4I1Q51$0 $&1M*N^2,6N_*8CD['LUT1\S?L"*503,A%
MH;1"-&!V:QN=CWH,V,VV8)]1S>YPOXDYXX:-H[),-1;XS*XUJS%GHIXY%,>S
MX^,?MQ'JAH2;7%:2&:8(Y,,X&5554:ZZAEF@P&V[+;(Q-?1P/#P71$IC:5K3
MC@FT0DWG,:I3GK) W/V0Q0AVAC3U=#Q9[2/^H)+6W H@H\&_D._ ?X4H%2]<*'8W''O,]
M,I R4%U%K/JEQBT ?],7#WL2(SC"C7BXJFQ
M16,06MM8O-V8,QV1R]!W,=UHV4:/^M6!''@FZ--.8A3ZC*Z(3G*#N@9;QT5P
MV,B4=H5=JZ%F#OKT5<=]U:3ZZ=%;D5O%JS2R-]MG=/X=?A]O[>7=I
MW6WOKOZXZZP4KCV:"H@FLV=/)AUZVY=@ZWB%36W A3@^EH1)R/$&K!?6ANT+
M'S#\3^/L'U!+ P04 " XB&I1E /_+$\$ #E"0 &0 'AL+W=O^OWT=*=AQ@,=!B+[9(W7WWW7=WI,:UL5]BTKY1U._YS:?BX"7
M&N7B+]6-[0C&:>6\*5IG,"BD;O[%MU:'(X?+_BL.P]9A&'DW@2++.^'%=&Q-
M3398 RT\Q%2C-\A)'8JR]!9O)?S\])&5\)S10EB_HR> 'JU[:
M8MTT6,-7L-[11Z-][NA7G7'VTK\'7@=RPSVYF^%)P"6771KU.S3L#_LG\$:'
M9$<1;_3=R=*?LY7S%JN_3L0Y/\0YCW'._Q=13V*%H;QRI4AYDF#J'-LM)].+
M+IW(9:[IH[!I#MD&;SM4,PF=T8R_5I4CUIXM_*3VA@1]D"DFK+%86%-(YXS=
MT8/Q3$]LT7$B3L]L8YDQC+Y+GYERD9'/F6SH>0*0;TTY;G\W:+2T("@M[XD&
M>L[)#297*9K=/KT/6%F5>E@VN>,]^V@)^UKZ'*<.K2L+#I924^#D;F)'D+1 XZ4.UMM:%:62J9QNT/&TOSAKD,X#X/3
M"UZ!0A3@_FY&JQVA?ST7*Y!Y$WIX\*Y+.$H.##/V0BK7(<<8?F<*'+
M#OWRT^5PV+\.HL44;U%:HV06,[^'A#J58+GTV @: B<*/#C9'!%U<$UF3::R
M--.Z L@CEP;A(50XZFC0/_L])AARV;&PZ!I,--UQVJ0S&NSS>4W+A[M7!$!S
M_E9ICB,=>_/0.MF/]I]S0%^M/'
MZ5HQ@VN&6#*<2^'J4CMD!S74-B#ZJ);'!1F0CVBA)J$>#I>'BW/>MD47Y7.I
ME67,"#XWE<-9XUR4>ME(0LJXR.GG4?<2UZ5239URB=(%1L'89HTL'Z*M
M?A$=KJ\3_J^;H7=T]19L-_$#PU%4K;F%#[N';YA9SZ:C?83MWI=19F87IPU:LUW'']K;CQ&TP&EU#7;H)TESZOST6+V
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M> FXK1!>[Q I]^=#]M(L=C7-;I!2+]I[6QNZ:'V>&1L^CN]J?MW0OIB_(X 0'I7<$T
MF[P_')'O7AW=(+HFW?0H7KP;TF>%AQI[V8#UE8-@_4 <#$^_B[\ 4$L#!!0
M ( #B(:E'$[6<)D1@ &U) 9 >&PO=V]R:W-H965TG)ZZLN%7BH_LBO=X,G,NJ5J\='-3_W*:57QH&5].CX[>W"Z5*8Y>?&,OWOK
M7CRS75N;1K]UA>^62^4V+W5MU\]/SD_B%^_,?-'2%Z3\RA+7=/?LI"@[W]IE& P*EJ:1_]67P(B[#!B'
M 6.F6Q9B*E^I5KUXYNRZ0V9J,_>*L\&L29AD[ENG5X:C"N??%*^]*9%7/(
MSHJ7G<<+WA>JJ8IK.2GZ_MK,&S,SI6K:8E*6MFM:T\R+M[8VI=&^^#[^]<.S
MTQ9DT>2G92#AI9 POH6$Q\7/MFD7OKAJ*EUMCS_%=M*>QG%/+\=')[S6JU%Q
M<38HQF?CLR/S720>7?!\%[?,=VC#_SV9^M9!IO[GR +WT@+W>(%[WW8(AUAY
M?*+?= %]=:K5A8'$%PO(9+V!]LR[&E]6?*RE7:YT:T@;"MW<&&<;J%D[*MXO
M-$2KZ6;85N=HN_0Z1."SYLV#M-5"015*W;60A;I8.5MU9>NQPN^=<>"+6N&[
M&SR:.;L<\ 3&0^>GGZ"&16L'A6WFEF>[TEFMF&&17<211M_0)-K1T &8#!ZHS\S_3;'1ROG _ V6O+$USHI(
MTU]@CBN#X]%T'."K;Z&3!DN"^[9S)0@Z(I'WDT3>/RI(+Y4'D5CA+::% A
M')+'/S$-RYDJF;O-AMC6-:JK^"QGIE%@-+9C&G$Y;+IY#N+'+!Q1NW!:\S?@
M.[@F!D23 2F@_JU>3L'>: /XQ?'9^>-B@:FF6CAZQ)29IM7.+&_;!8C@^6F,:2#:
M'7LF#[4H_MDIA\&8_9U>6=="30IR.\7YV?"?/'3B($(0Q?,S8L8[46F:]WKX
M7Z/BC9!B5Z8)5@22!*DES1Y 3LK%+51A?W57D>;6=:&J3W Y- 8FO01I4$#6
MU:9F-]#0,!*ULG-B(/H!/Q0\H-+$U49#$#TY#]&$F3*.>-X+ 6:#N&9$K:PW
MPJ=6Z*W(C-'.96-DUFA)3 */*^I1*H]] 5EX7H>'X45C*U++O2%_5GJ@;(UM
MTZ9,34H)^Z+8AF(G-&E9 X<6DD#;#
MCN*=)$FRF5%Q*89B3YYFUK8@31>5\65M?42S94'M&>W)7LH9']."
M _)^6#$6"DQ@I;)+T])[J\[YCJ "!)M9T]%[@4^L+==X]:59LDA$=GC4?'9R8R\@J"(")R/A"[DG.:9IPT38=I]G7Y'UBDUIDAP/;H^<_*
M07;/+T3DQ!>#U@KX5U>L64 >%6]MJFH^)4'M$+9]%T[QW:=",4?P;;0
MOFAM3UL@HA>PD]8Q)+I-S\CR80GHN<9T/ &P -O0LNR6 9]%;+'$B 7%/B /
M^Q+9!JL@QGYW#&(00!U8>:T@0ICYN_/QZ S!0EVS'HGWW!621U'&G L!4F58
M;0)/B TK $$2SM:VV(_R7A/;Y!,V7'Y>V!H2YO_CWQZ-SQ\^+>C8VXT@L5N$
M-V,*>0 QT7AA< )Z$W\,USQ(N.;!44#RMI"7E&BI/D&JVT.K3'#6G2]>&BLA
MP0 (I!SQBS)7B8R(()Q>!I2^_Y;(O:[98A$#UXJL&!EO
MLE?TO,&QM0X\WYWAB+ ?/-R#;($]JVN9-LA,T6:[YDT$NX^CQ]J%KG&JC0HP
MM,R%[YBB/$R*\O"H;'_P#&RN@/^(OP=CT:,S4#KIB8<%T<]/V/RY&WVR-RWK
MB:"0! MO40G:(SDV'>
MNN4J '+R@FHVXYB592>*PC(IHYA#'EH;-34UPQF:_D8W79B4XS6O@QA&<)*#
M-:WRA7O(;QB:4"T?J?AHG.>:@"VT3#C=:=)K54@R M\A%H>S7"\,G"B]
MH@$_F&TB *HV?R01SGGH\\#/153[07A[B28;("9+I1 6F,=-&LDR@I0D0
M4\U@!'@,!T#?+ 8X9-B53B-J^)5M> P#"WVCZHZWM%YH!AKTC^8AM(01X8>B
MD BW[)-31$<1PGSN])RQ(3/4*8.]Y#F(RG93*,[4 CHRL&8V;"@..,+UK[-
MB1I^?<,W85RCO[1AKJ;ZZAD,DFPT&EO-J96_.6M# DLH?0#$=:-KNY+8NM42
M(XN"0(]I^?$\H[!KX
M&\"UZ'Z6,+O1R?+ LU1RLG@O"=T623(=(PXXU%)2?_N)P(K22!WRF*78&FR2V9FR?@GJRFKH/S_ _
MSD=SMF[648(L0(4;+
M' ("8-<.H4U+2B/JF-MA!/'=_8>C>S%,"%'"H5WND$W**$?*,4VFE"D#*3+%
M2:,I&8@9,41+/F!)02N-M]/:S%6 -VQE66F@\UU(^UCL-R#1/E @D&0#8SH'
M\?I=,F=$/>@]'Q4O%5E**W%@L'FTPQA0;NW:9;!KWU_#'-J5*3'+_>&]LQ^>%*^2ZZ=YM6E7OC)SO<6E9);J-3NCY;OO?J<"%!9@44K,53
MIN1&YAHR#I3 /)P(:"F!X)]NE5NDEK*]G$P>*>\X&ZQJENB<92LJ-I')?2KA
M&=O7K@%&:2@VB[:3O'<:DZ_#UI#2DK EG]FF!B$AN*-6AF+Z=N%L-U] /Z";
M)4VU
M!*#(DT[;;%9:DN(JRHRSX\$K4]5\+C S4&I\):1+@['I0X9F/BK^9M=DT+/L
M3E%+_%LT'5LV6KYK81C-'Q34(GR527!02U#'B8W,NG)BWY.]*'7P6EOBSOEQ
MK@"13 0."BJL>Q\>EPG$KXGW=!H4>&[9R$&V-*B9J1LK)2@RXCQ!_YR"E+H>
M%6]F^SK(HDI'S#$M;8 (#>?H4_IUL&TF3(C2(1_Z2TC^YYD>IEF\,2^[)J.#
M6*P^B0BCQE$[1+6ED\$,AM9ZK886X"O;)
ME\3QJ<+Q$8:- 3($!5Z%&">Y2Z(@8CD!-IGQ@4&8.[4DN=M>@]-U@@WN!&&F
MG*[F@X,^MUPK#AB1^22EV2&\5VUFAIP2V&NAR_7.V,A7K@9"J92$PCRASPHM
MN2G?<9D2S%)VG^9T$@(0-,MM$\O70'2&]SMSM!1GCI?J,XMYY]+2'0?=B4,K
MM8GFC-+.H.%[P90TCK4\OO$#;>74NGB0H*L,UE0KK[=R@C6'AG2&+#9]U 5;
MXLVT#M:,3(3K5FVYH?-K)9^YYSFBC2 ABN;6^. FZ.S)/T@!-CE2"M@Y@+0"
M?Y/'H "D\RE31K9#.T(#,4HDP^PY^;K65%GS\MZV=XB%C;A>GOCKK=7V((#4
M5N)** P.KMEY/M@9O0(]?#(M@MB0+CHVDL+S;%RA&\IZL7+TC@?^MB5SD(I=
M(5F<)MP*D7I)D#*/^+C=?46G+C5O""6?N]LJJ-&Y:<[5QZ:!5Y/>(R37+HRE
ML!9H:DJ1'^<"G-AP'^M2V[""= UIH*R%A^AJ(#6
M+Z$CG 2[_OAR$-DI*2[AIL3\^'9CDU!SQG/+\@9_%;?%:!Z^U.N>2*#&8NJX
M&,%5^TTH&.7OY#*ABE1N414UA>@@)K&6TX?IF4WC"E'(613?]T%([F&I)$WU
MOSY\!,]XGT12Z-VZ&T_[S!!-6*K.;]7"@*O)B5:2'"9[IRN&8/WDT/%TN%/-
MD8Z!T:B,0-<8]Z)*B@.(LR%*WT2E#8"B%X
MG?X65S5CE"GA,H'S,F3'UGV=N]1<\864>78\C?A-1O/*\ ,N+&D;_>HCQ[*+N=Q@A=22O&
M$$QS0$10;F"RC6R)*ZY@YQ\A!6N:54<6T,OFPJ1;W'J?TIG2X5&3W6;9^NK@
M@1C-GVA$<4XHJ*_MSA=4Z@GT;/@HY;V+_+T:@8=OGQ14#!T_>!JGXMKH^.G'
MF(;P_>Z!\6+E^??.
M'(1]IIUHB[,D$#'0(D%(U4D*Q/) +5]8_";]Y,!-TX!? (Q W\*,YFQ$?K'
MO([?+\_SHCPF\FW_/3X"J'J7F-E7+?L>Z6S'DNK/V!D LY-2EL]T# #ET\
MN/?T8O3XJWG]P]@*HK0P-#41A4._T7W"?XNY.%$5A 9FVU?^REZGKS6E
M#&V4R[OTGN[$B*%?)G6Z<;_,@U$H#L3F@<&Q0.$\NQER?KS.3^F8@_C_3@.+
M#QSZ3*XOBT?WQL6P"%_ST52:8# QP,P8HCI'$1^KF:%48,VY(,6-AWHE^9S?
MY$CASOZ@M*ZCRP-#.QMR+,88E\$!C^QQ;3)J>=?D+*0#:Z%)VKXY!08JY5EYC-4G:D7:E$[:QG9D)%SHX,81O\AB2-SKPC0S8('ZCD?BUYF8,87&4
M7MD>7G>1OW_AHQ=&*1X. IY[=T
M#R0D)B&3D)2EW#:S4W LT0E&!Y./-I"30GLF$_;828G&N,XG%)C
MR?!O73EBK4HB3K)EMX_;%XP=TA$SG91N9TDFRY.3N2N8GH-5N2]Q"^A+9ID>
M_/CUS/Y?JGOV&=YMP,'%X]#=J>5I
M]NTQ'S/N?),';D;$H2AQ"4;H]
M(O74 $YBN.96@:SZG'>L4'IG1%W_,\VWM83=L>.PBGD3?&1=G3O5Q/+0#17M
M!N084S::B]C9]9!(!CE/+L60ZJ25*C.CY$XPI)2;39V.3!(-Y_X6V,G %2EZ
MVE4/9[D,:\HV/LP0U6$>)J[UF]SF6D%UO1 0+0A:YJ!ZGR28#,^$) H"J8#:X(4^W\UIT@:I,+9#R3I9X)PUUV#5_P#/7^.A:7
M;W1XU!K:UG8E6I)*^7.X/LBRZZ6P2Y9/2'Z"Q7F/"=6
M;D*O'IEFMF>)ID-TA$X T7.N@3!,)8?;4T'AH>_<)KR=Z&!^&"<6EMF0N5\N
M,[1FF);7C :/BG1_F?C\^"5@2H,T+75$5W85+_V^X0[)@]U.!P7^Z!*'TS)[
MZQYLK4(\,^GF'6 )74*1DN/KR?7+T,/)=V:S"T)SJO_RG32&.*FH[^/=V:R9
M.J:\^GM;LUN2T!'^DXC$KNW0%!YZ7^(31F(AY$I+$HV[MY^6MJ*0P$NWP2U$
MB8JE/<$(R,&3"#"]AGH8POW?J9Z;1JX5
M2:".""_)4[A/EAOHV F9L&%M+7=QG"2<(NE#MNLG8=L<*_1W]CA4[$2W/3GH"G?L0O;&M3P[]2OWMQAC)4Z(]71UEK?'X)G[D>@^@HGD_#7:
M.QX?T]Y6K@F.BBM%Q;BD@(;]KZ0[69%#,)IZ<^^HK.#87ZBGN4FGAN&[*J'<
M\NQ]?2;<^^:^7=MX9%+<8WGE<(Q23/<>G@W'9^%>0JQ\R+4BG2].:](Y< X_
MPR@SK1@\4]U]?Q3]A$4KJA#ZG:@)*]B 4B5)_[\2GHM_57CD1O@WK'CV_T?<
M#H&DT^P7<);:S?EW?KS\2(?\&$[Z-OV6T$1^0:=_77Z(Z&?EP J/@'F&H6>C
MA_=/)"L6/[1VQ;^G,[5M:Y?\YP+V1CMZ <_I'G3\0 ND7UAZ\;]02P,$%
M @ .(AJ42X$$OV& P P < !D !X;"]W;W)K&ULE551;]LV$/XK!ZT86D"S+-E.;,\V8"=I-Z !@CCI'H8]4-))XB*1*DG9
M]7[]CI0L.VT2;"\2>>1]_+Z[XW&QE^I)%X@&OE6ET$NO,*:>!X%."JR8'L@:
M!:UD4E7,T%3E@:X5LM0Y5640#8<70<6X\%8+9[M3JX5L3,D%WBG0354Q==A@
M*?=++_2.AGN>%\8:@M6B9CENT3S6=XIF08^2\@J%YE* PFSIKE,/4LQ84YI[N?\-.ST3BY?(4KLO[+N]0P^21AM9=<[$
MH.*B_;-O71S^BT/4.42.=WN08WG-#%LME-R#LKL)S0Z<5.=-Y+BP2=D:1:N<
M_,SJ&G6B>.TB)#/8-)HV: U,I+!M$V7M6YX+GO&$"0/K))&-,%SD<"=+GG#4
M\/Z!Q27J#XO $"D+'20=@4U+('J%P QNI3"%AAN18OK DOOG.M9&447]]<8!X_Z L3M@_!KA4YBO
MF"Y
MI&$EW&C#J9N0^2R-WR^Y_+\C2C/Z_OS3- JC7Y^-VI5P.H7/N,,2PF,6J#SG
M]DJAS8YZHK:>-:04QF-_-HMZA.._,T=3?S:Y[+"B9UB/@^T A9^*PYC*QYY%]<7,!+US@XZZH5JMR]'1I<-V@;;&_MGZ=UVY5/
MV]NW[9:IW%9&B1FY#@>7$P]4^UZT$R-KUZ-C::CCNV%!3RPJNX'6,RG-<6(/
MZ!_MU;]02P,$% @ .(AJ42I@MZ(^ P T 8 !D !X;"]W;W)K&UL?55=C]HZ$/TKH[2J=B66?,%"MH#$1Z]N']JB9=L^
M5'TPR02L.G9J.V7;7]^Q$^@B+?L L<3@](_S![1PF,EI)D&>VOK
MNS T^1XK9OJJ1DDGI=(5L[35N]#4&EGA@RH1)E%T&U:,RV V\;:UGDU48P67
MN-9@FJIB^O<"A3I,@S@X&N[Y;F^=(9Q-:K;##=K/]5K3+CRA%+Q":;B2H+&<
M!O/X;C%P_M[A"\>#>;(&5\E6J1]N\[Z8!I$CA )SZQ 8/7[A$H5P0$3C9X<9
MG%*ZP*?K(_I_OG:J97*V'\/QQ:
MW]$H@+PQ5E5=,#&HN&R?[+'3X4G .+H0D'0!B>?=)O(L5\RRV42K VCG36AN
MX4OUT42.2_=2-E;3*:"#DG9OX)TLL#B/#XG2B5=RY+5(7@3<8-V'-.I!$B71"WCIJ<[4XZ47\%98
MHM98P%(9:WJP9#6W3/ _6/1@K;%FG!9,%G"FR(J;7"C3:(1O\ZVQFKKH^PMT
M!B9;P.>5?1FJC64LW5W1;C*4R"9<.H%2"KAV7.[CB
MDBRJ,52CN;X#$MABM:78H\JPPKRSQ,X29^#OZ(TJ;QJ#QQRO(>D-;C-ZIKUT
ME,%[)R.3\&7^0+'V&==Q
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M '0[/]N-5;6?65ME:0+ZY9X^.:B= YV7BH3J-B[!Z2,V^PM02P,$% @
M.(AJ41D1S1"E P MP< !D !X;"]W;W)K&UL
MC55M;]LV$/XK!VT8$L"V7JS,<6(;L),5#99N1MRU'XI]H*233(0B59*JZW^_
M(R6[WI(8^V!+I.Z>N^>YXW&V4_K9;!$M?*^%-/-@:VUS$X8FWV+-S$@U*.E+
MJ73-+"UU%9I&(RN\4RW")(I^#6O&9;"8^;VU7LQ4:P67N-9@VKIF>K]"H7;S
M( X.&T^\VEJW$2YF#:MP@_:O9JUI%1Y1"EZC-%Q)T%C.@V5\LTJ=O3?XQ'%G
M3M[!,G:+AV(>1"XA%)A;A\#H\0WO4 @'1&E\[3TCG>/I^0'_GN1.7
MC!F\4^(S+^QV'EP'4)6F&?U.X]]GRN'%ZNA/'_L.MLTRB O#56U;TS95!S
MV3W9]UZ'$X?KMQR2WB'Q>7>!?);WS++%3*L=:&=-:.[%4_7>E!R7KB@;J^DK
M)S^[^--N4<,C9QD7W'(T&190+-Y2RTA.^LPKS'6G58R1M84_B@I-T:^$T6
M6/S;/Z2\CLDEA^16R5G #38C&$<#2*(D.H,W/I(=>[SQ_R9[STTNE&DUPI=E
M9JRF+OG[3*3T&"GUD=(W(MVINE$2I36@2G@1]S5MSP-V$.(D]5S1R3 6"Q>!
MOD*I!!TQ+BNXX))V5&N8+,SE#9".%NN, YBPCWF_4[L=N(I/"(U]VF$ 4@E
MAWFK-?& GR$>C"=3>B:#Z73L:CQ4Y;!DN3/?@T JNH82$2[B2_CEI^LD3F[)
M*4VC7@"A9#6TJ&M0F> 5<\?2P'B2PI1^'Y5E M0+GB[PY&I,SZM!&DT\^IG@
MS"O^DIY&&EK&5X31,*A52Z0:MG?-#E;!AI!(4OC$A, ]K)A\AK;QDX>L:B-1J7O,K >*;P_QEU*VY/>$C:*(E*$;3Q!'
MP]^I!;1OA3TR#4Z3XA4EG!$K"N[D)QPNN]%.JQ$LO7HO^V5 L-S0_!.4-<*6
M5,X0G3BY8,;PDCM!5%_H0\^2LMN&/\P[ZZT#TQ7G%I<8$FNT6AR%8#N
MKHEN857C1W.F+ UZ_[JEFQ6U,Z#OI2*]^H4+<+RK%_\ 4$L#!!0 ( #B(
M:E&&-5Y@+@4 /H2 9 >&PO=V]R:W-H965TE^_(V=
M-+R%E%U5VB^$./.,GQG/>,;NK;GX*D-*%7J)HT1>U4*EEI?-IO1#&A/9X$N:
MP)V")4>J#9[RW)@LZH>EI.!;PU"RT!BVDB&4^0H/.KV@!?3G!'
M XS$9T;7##FF4AZS:._6*#"JYI70P&=DS12#WQ]1W.#VEJ?SR-I?M$ZE[5J
MR$^EXG$.!@8Q2[(G>TXIP(Z.:!S*L#+ =ZI@&X.Z)IPR-;/+/Z(*-+O";Y&0DN#-OW'1)!!PYJS
M1 ?[3 GXR@"G^B,J?<&6)O#X' U3"0)2(I($:)8E@!Z?L47"YLPGB4(#W^=I
MHEBR0%,>,9]1B2[0( B8UD(B-$FR)-0ZST94$1;)<_0)L00]ACR5H%O6T6^_
M>([;^EV/WK,H F$8E"$1H&YKK-=48*8FV_1SDX:92?81DQQTSQ,52C1. AJ4
MX$?5^&X%O@GN+7QLO_EX:%Y[
MND8?R&O\@;QNOH/7^.D!G>6QR]^\_0!9-%(WE/Q546@65EJ'2.D(%IDCC
M-"**!KKNP!RJ+(LS):Y1HFORJF\[V+&L=J^YV@[B$^5N2^3L3KO==@NY'6O:
MA37M2FL>N8(]S2_:>)'5[*.4XKGO$5K>PU:VT]?/@$3H8GX)]SQ%%_[UMTF4YG&GJ
M;A-H='=)WE7+[%#L%!0[E12G@J^8:;6@R"!8AY0B$L!&C11Y041*"/IC"S#J
M'#BM!5UA.2&O(.15$^(*IF,0(TORJF=&BF=<4@61P=1K62AXAXML;3')Z)XB
M=.,=^+C5<,I-ZA8F=2M-&D.$J]<+W40&R.2U$]AX?362%_\*-71
M-1<\-KY(%7GKEB@1"6RD$BVIR%H7= :M2U;WSB%]CE; 8H6?+B\^[:^*W);(G(DR;&],=.N-/.!YML.K/M4,-A[
MIA0>01V-A8"W:RY$=H"K0R_\);VHZKB_M'+O<$']9L
MO7D<6ZQ-R<;5-7L -3J5:,CX$C(P)G4XD_B0CX/YG$7,T!R#H_:WYMW9-D43
MNS]]?3;E$5?7QTD"G0@T(?H,%9,OI@!=\'4")LOT6;* P9&N-/6J];I6P[)^
M+3U-_2#PY@> F5.:6^?=F(J%N2R1R'@W:U.+T>)"9F"N(?;&A_CR&I>,C_#E
MN&S\%E_>9=%%^:4_@S5W"F-W]#
M2@(JM !\GW/H(_(7/4%QW=7_'U!+ P04 " XB&I1*?:.P10$ !Z#P
M&0 'AL+W=O^_[.MJRA.J.W#$!;]92)=3 5&U\O5.,KIQ3
M$OLD" 9^0KGPIF/W[%9-QS(U,1?L5B&=)@E5CU)A[VG!W=\LS7V@3\=
M[^B&+9BYW]TJF/EYE!5/F-!<"J38>N+-\/LY(=;!67SC[*!+8V2I+*5\L)//
MJXD76$0L9I&Q(2C\[=F)&/M?M$ALPT\%*7:R"1S!@0)%\=_^BLK1,D!
M]QH<2.9 SG7H9@Y=1_2(S-&ZIH9.QTH>D++6$,T.7&V<-[#APB[CPBAXR\'/
M3*^9CA3?N9+*-;I*-1AHC:A8H<5Q:>WS!=\(ON81%0;-HDBFPG"Q0;BSV#-M$O?JAE&=*K9"U*"/E"OT
MC<8I0W9YT1V+4J5LEBNJN49OKYFA/-;O(-G]XAJ]??,.O4%^
M@8I87GZ4L;\ZLB<-[!=LUT'=X *1@ 0U[O-V]VL6@3NV[C@\=?=A'?+%(/EB
M$!>OVQAO:=#"\N8&JGJ!9GM@3)ZFAH.C';*F-@N[_NR5A-T_8=0E[
M#0GS18OL@!6+5E?*8ZB!"V7583_M!L!Z7ZY7U0:/1KG-"<9>CK'7BO&K-#1V
M "\J,!UV7?06+WKK M$$GO/?T%V1U*:.T3%QOX2V/^R5.)W@[>=X^W\&[T9)
MV'BI #6.'>P-J'#M2O0KN+OUF X.N]3BN"=A(^
MS,.'KR,I."B^*,'+B4H6JUS47B\,GY>^QHR,POZPOO:X]/7#9U2?0/7O.XL.
MVL@]4\*VB2, YQ@1/2*=EZ^M/H7(XU=2>5S(//X/G0"X7<$_.9&X+T3B4Y.PX:HB-V4OY!BWZW$E^Y=&B<)586U*7R@K/D=:
M/VC#XY_[$#
MLDAG[ !2.M22%]P!6;#!Z1)@_&P7U)F%X?.CFU^Z&-E;Z0U5&R@\BMD:W(+.
M$(BJXT7O.#%RY^Y*2VG@YN6&6[@<,V4-X/U:2O,TL=>O_+H]_1=02P,$%
M @ .(AJ474.RR/6 @ 0P@ !D !X;"]W;W)K&ULC9;?;YLP$,?_%0OUH97:0O@9JB12FFA:'Z9%3=L]3'MPX A6 3/;-.W^
M^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MYQLNF'S]?@W@."V.HW'<,SBZ:VYH#LL
M9-?(<8)_1D=\;LOG#O(]J-K@ KW,GV3/1D#>\"8#6;<"1!]H[2^E]FC*&DG(BSA)Z_R7L6KACIQ_0;P']0<"%7" 1SI!@1%X;QMY'
M[7>B!\$I88^-?::$04L8#+^(D%1%K!XNXA!5C(B//68?9= A&(7N">6PS1'E
MN*4<#U+JGNSC&7=C.=X)3]?L^T1]CRA/_G&>C;L-N2GC\^X>H:A:[OG8"9
M!Y]X=;Q^PVQ+"HXR2*3,N@UD7JP^LNJ)H*7^ZF^HD&>('J;RE >F#.1^0JG8
M3]1!TOXWS/X"4$L#!!0 ( #B(:E$ME! LP ( #L' 9 >&PO=V]R
M:W-H965T]E+8COG^\YW+CGN+X5\5B6BAM>*<37P
M2JWGE[ZOLA(KHB[$'+GY4@A9$6VV&?7=V)X=]
ML=",3J&IE8#KS0>S^XI[-2VP-_V)^3&4Y0/\[OI-GY#4M.*^2*
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M4:\7-T:?I":-U.2HU+K\3/!92Z.L0$P9G1'[@^VMRD\9;$7:,T"3K[-;8;C>VC&B=HZHLY
MN-YZ@[$@9D;Q'-PYU2NXFDE$UVYO,#$19&:(/1'&< 77A#\?Z;M.(Z'S/]JZ
MV]!WCT;XA>CN=&NP585=BS!)@JTJ^!NCS5XK
MWXF<4:Z,\\+ @HN.J:*L1W6]T6+NIMU4:#,[W;(TMQM*:V"^%T+H]XT=H,U]
M.?P+4$L#!!0 ( #B(:E%*;/?08P0 ,$1 9 >&PO=V]R:W-H965T
MXRB1
MH]9&J>V=X\CEAL54MOF6)7!GQ45,%9R*M2.W@M% @^+((:[;'Q_8'W3P$,R"2C;ET9]AH#:CUJ"% K:B::2^
M\/VOS 34S?B6/)+Z/]KG8_N]%EJF4O'8@$%!'";Y+WTUB3@" $\]@!@ N1;@
M&8!W+:!C )U30*R2RT<"6'>C'I=&0
MX##)*FNN!-P- :?&]]_24'U'7P5-)-4/6Z*;&5,TC.0M^@4]SV?HYMTM>H<<
M)#=4,(G"!#TGH9(?X"(]WP5-(DD$-'@:",UEF:R2?YY*1A>:(V$MTG
M 0MJ\%,[WKN$G]GQO@7O0"*+;))#-B?$2OA(11MY^ ,B+G'KXODY^,P.G[,M
MP-U&^/W5<.S7P!_L\!E;'L2?PBNY](K*]#2?U\ WC:B4B*_07/'E"_K[-[B/
M/BD6RW\L[)V"O:/9.PWL3X(O&0LD6@D>HR6/8[ YJ6?BJQ438;*NJ^>C7LN_ V=78V6;J&E:]7RV4P(,J2J6T:S[MFTY93YHST?T>G6J^H5JGH7
M,L1 EF"!28M45,')CD8I0S>P\ ,>151(M&4BMX;;.NGY)/UCZ6W7Q57Y#Y=&
M52+H%Q'TK1'H-BG1Y]KG66$<%(R#-ZA)OV#W?ZX.)O[94_:;B@^[90=PK=/.
M85*P];]0^<1U>):(\%%[P6^0,4Q*?F(7;WJ2E"GHSLHR[U)UM3@Q7-WC5=(A
M?D,"2Z/"GE7#[VF\@#4 09H.N>3)C@EUA2#O3-#)PIZ:(1A7U@89]+T&V:4#
M8KL%5E.7;L$ <^'ZK?$0S<40.FV.^>I1\&K,]A4$F2+
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MG*O#239!\=5F_ -02P,$% @ .(AJ44+"(Z^T @ &P@ !D !X;"]W
M;W)K&ULM59=3]LP%/TK5Q$/( %)DWX :BOU:QH2
M2!6%[6':@]LXC8=C!]MI0=J/W[639@5*QS;QTOCCGG-\KJU[VUU+=:]32@T\
M9ESHGI<:DU_XOEZD-"/Z5.94X$XB548,3M72U[FB)':@C/MA$+3]C##A];MN
M;:KZ75D8S@2=*M!%EA'U-*1P]LLW+!E:NR"W^_F9$EGU-SE4X4SOV:)
M64:%9E* HDG/&S0N)AT;[P*^,+K66V.P3N92WMO)9=SS GL@RNG"6 :"GQ4=
M4+T:DD+W!YOV#\Y[^AE3C0=2?Z5Q2;M>6<>Q#0A!3M@#(LQL05H#P):#Y!B"J -%[
M%9H5H/E>A58%<-;]TKM+W)@8TN\JN09EHY'-#ESV'1KSQ81])S.C<)&QC ERCS!K2)"$W>%&@['U!#&]1&CS_?@_?1>NT_W/@?AGL)9S0_A2@X
MAC (@QWG&;T;WCC?9>?_U"?_K/XL&5']&"+'%_WM8X!O5Q@*EX9F^OL>H68M
MU'1"S3>$KJ36@+0QTUKRPDG(!-_U#ZF8>3J1:X''T,54JP A[#I5CL276[UFI_[)UV:J'.1]_IN/,JT]%9\#+9_E:URZA:
MNC:C82$+8U9E*RHG1N:NULZEP&ULE95=;]HP%(;_BI554RM5)"0A_5B(U$+1*K52!6MW,>W"A -8=>S,-M#]
M^QT[:114H.PF\;'?]SG^RDFZD>I5+P$,>2NXT'UO:4QY[?LZ7T)!=4>6('!D
M+E5!#89JX>M2 9TY4\'], @2OZ!,>%GJ^IY4ELJ5X4S DR)Z5114_;T%+C=]
MK^N]=XS98FELAY^E)5W !,QS^:0P\AO*C!4@-)."*)CWO9ON]2BV>B=X8;#1
MK3:Q*YE*^6J#^UG?"^R$@$-N+('B:PT#X-R"H;S&\I?E[GNJURA7MR3:#LD"@X)V$0!G?/8W):
M9SG;P1K\!^MY,B2G)[LHP\.4(>1(Z5I*'9C.Z.9R6?L4;'LZ(#+!]/NSGR
ML#GRT,'C/?"7FQ_D1FO0&@N$T0>(44.,'#':0WR06I/MF_3K 37DWD"A?Q_(
M$#<9XH-S'E,D$SDG):9B4PZ$8V/7%:PX5XYCJ^HZBSM1ZJ_;5ZO2)"U-;ULQ
M_$@).E?;FKN/FK!SN:T9[>(DC:;:"K_U]=IB_DC5@@E-.,S1%70NL$2HJD!6
M@9&E^Z"GTF!Y<,TE_E- 60&.SZ4T[X&M$&PODN>1Z>BB?!CG-JUT"U"VAOZN_@[_?]
M8[N-&Q1J0_%#AK$"%:.\"&&F5/[.<8I5AADJ+D2.N=.0P1#J. E^R.J0*L1,E5"&=="-CA8QQ";_86 HN[%3$.X>/9ZV^E
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ML:MDL'.NV3?>F5I08UJ,=0Q_2+/L(=9_$1?D9"W4AU(_#J]]4Y)RANW#']PP"E!;!S(AR9/N9H[*2@>PA&"-I2*K8>2[
M1/D"5ZH]3E4RKMD_0$K3M"%P7F+A;"+^9N1_NF8%D2
MJ@AOO(S$,>;/K@H:K]!2_UW8XNOY,4Y02=6B2X:PMS_CF)1LWLVZ-PO1S.KM
M3^;QO%G=L/]/$OT&4$L#!!0 ( #B(:E&7BKL-8?20$3;
M8T.P6BP^0"X99K>]9!:GSAA):WS
MW1W=_ (9GP%OWO8:;SY+Y<'FPL,7:YJ-U(_M-+B*-%A&EX==NTWBA?V?-)JJ
MD@7DIFAJT'Z;1PNJ!=1N+3H5T4_LIMN5V@1[(@7?9"
MXH"]+3O&B#SS63Z9+28YPZO%?'J;CY?8N1Y/Q[.;"0L@,P(R.R+D]RR /"$@
M3XX"N5AB\VTR"R#[!&3_B)![F1P0D(-C0IX$D$,"4I GL:%S,$5
M5F[:.#,5NVZQES\$*JO6>=42K)
M(JODP-MX")%22A99*0=L=QB2/)I$MLJ_O=>QAIB49[+8IY-0?H>S2/DEZ_R2
M[L[')52XY&E'NCMN[OPJN?@-0
M2P,$% @ .(AJ4:_LDZ4X 0 'P\ !H !X;"]?N/B8UN WLCU1@%Z(]<;WZFW#X^6_-SS7//SWTEU&)^E^?AI^=Q5DNY0*8&(W&K'0V@4W#U&KDL\D3U'*E4_:\P<=1.3O- ^B89X^[
MPM9KFDOOM2IEPGVVMM4WE^'>H<#.KB8VRLAB)SKH=TYXPK"[
M\HO].YD^0ZR>+P?
M+BR[>436+9>?\=<9'_7/S"&(Y+@BDN.:2(X;(CG&1'+<$LEQ1R3'/9$$0E
M"!6B"54Z%JYP*6#D5L@HJ9!54R"JHD%50(:OX3[*^
M.[?\ZR_5=BV,5/;@S[K? ;-/4$L! A0#% @ .(AJ40=!36*! L0
M ! ( ! &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" XB&I1=Y%+>>T K @ $0 @ &O 9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4 " XB&I1F5R<(Q & "<)P $P
M @ '+ 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( #B(:E&Z
MZBH', 4 &P5 8 " @0P( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @
M.(AJ40M141Q5 P R0P !@ ("!/1, 'AL+W=O&PO=V]R
M:W-H965T&UL4$L! A0#% @ .(AJ4:\>,9=W"@ ?3\
M !@ ("!(R$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .(AJ41 E):,Q P RP8 !@ ("!
MFU 'AL+W=O&UL4$L! A0#% @ .(AJ40WD6[=D!@ WQ !D
M ("!T5< 'AL+W=O&PO=V]R:W-H
M965T&UL4$L!
M A0#% @ .(AJ4<3M9PF1& ;4D !D ("!L&< 'AL
M+W=O&PO=V]R:W-H965TB/@, - & 9 "
M@36$ !X;"]W;W)K&UL4$L! A0#% @ .(AJ
M41D1S1"E P MP< !D ("!JH< 'AL+W=O8"X% #Z$@ &0
M @(&&BP >&PO=V]R:W-H965TN0 !X;"]W;W)K
M&UL4$L! A0#% @ .(AJ474.RR/6 @ 0P@
M !D ("!-I4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .(AJ44+"(Z^T @ &P@ !D
M ("!U)\ 'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0#% @ .(AJ49>*
MNQS $P( L ( !ZZ< %]R96QS+RYR96QS4$L! A0#
M% @ .(AJ4:^KXFZ. @ KA \ ( !U*@ 'AL+W=O
M7!E&UL4$L%!@ @ " EP@ )^N $!
end
XML
37
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
38
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
XML
39
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.20.2
html
116
238
1
false
22
0
false
5
false
false
R1.htm
0001001 - Document - Cover Page
Sheet
http://www.ctibiopharma.com/role/CoverPage
Cover Page
Cover
1
false
false
R2.htm
1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS
Sheet
http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS
CONDENSED CONSOLIDATED BALANCE SHEETS
Statements
2
false
false
R3.htm
1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
Sheet
http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
Statements
3
false
false
R4.htm
1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Sheet
http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Statements
4
false
false
R5.htm
1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Sheet
http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Statements
5
false
false
R6.htm
1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
Sheet
http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
Statements
6
false
false
R7.htm
1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Sheet
http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Statements
7
false
false
R8.htm
2101101 - Disclosure - Description of Business and Summary of Significant Accounting Policies
Sheet
http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies
Description of Business and Summary of Significant Accounting Policies
Notes
8
false
false
R9.htm
2106102 - Disclosure - Other Assets
Sheet
http://www.ctibiopharma.com/role/OtherAssets
Other Assets
Notes
9
false
false
R10.htm
2109103 - Disclosure - Other Liabilities
Sheet
http://www.ctibiopharma.com/role/OtherLiabilities
Other Liabilities
Notes
10
false
false
R11.htm
2112104 - Disclosure - Equity Transactions
Sheet
http://www.ctibiopharma.com/role/EquityTransactions
Equity Transactions
Notes
11
false
false
R12.htm
2114105 - Disclosure - Related Party Transactions
Sheet
http://www.ctibiopharma.com/role/RelatedPartyTransactions
Related Party Transactions
Notes
12
false
false
R13.htm
2116106 - Disclosure - Contingencies
Sheet
http://www.ctibiopharma.com/role/Contingencies
Contingencies
Notes
13
false
false
R14.htm
2202201 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)
Sheet
http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies
Description of Business and Summary of Significant Accounting Policies (Policies)
Policies
http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies
14
false
false
R15.htm
2303301 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)
Sheet
http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables
Description of Business and Summary of Significant Accounting Policies (Tables)
Tables
http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies
15
false
false
R16.htm
2307302 - Disclosure - Other Assets (Tables)
Sheet
http://www.ctibiopharma.com/role/OtherAssetsTables
Other Assets (Tables)
Tables
http://www.ctibiopharma.com/role/OtherAssets
16
false
false
R17.htm
2310303 - Disclosure - Other Liabilities (Tables)
Sheet
http://www.ctibiopharma.com/role/OtherLiabilitiesTables
Other Liabilities (Tables)
Tables
http://www.ctibiopharma.com/role/OtherLiabilities
17
false
false
R18.htm
2404401 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)
Sheet
http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails
Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)
Details
18
false
false
R19.htm
2405402 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Cash and Cash Equivalents and Short-term Investments Measured at Fair Value on a Recurring Basis (Details)
Sheet
http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails
Description of Business and Summary of Significant Accounting Policies - Cash and Cash Equivalents and Short-term Investments Measured at Fair Value on a Recurring Basis (Details)
Details
19
false
false
R20.htm
2408403 - Disclosure - Other Assets (Details)
Sheet
http://www.ctibiopharma.com/role/OtherAssetsDetails
Other Assets (Details)
Details
http://www.ctibiopharma.com/role/OtherAssetsTables
20
false
false
R21.htm
2411404 - Disclosure - Other Liabilities (Details)
Sheet
http://www.ctibiopharma.com/role/OtherLiabilitiesDetails
Other Liabilities (Details)
Details
http://www.ctibiopharma.com/role/OtherLiabilitiesTables
21
false
false
R22.htm
2413405 - Disclosure - Equity Transactions (Details)
Sheet
http://www.ctibiopharma.com/role/EquityTransactionsDetails
Equity Transactions (Details)
Details
http://www.ctibiopharma.com/role/EquityTransactions
22
false
false
R23.htm
2415406 - Disclosure - Related Party Transactions (Details)
Sheet
http://www.ctibiopharma.com/role/RelatedPartyTransactionsDetails
Related Party Transactions (Details)
Details
http://www.ctibiopharma.com/role/RelatedPartyTransactions
23
false
false
R24.htm
2417407 - Disclosure - Contingencies (Details)
Sheet
http://www.ctibiopharma.com/role/ContingenciesDetails
Contingencies (Details)
Details
http://www.ctibiopharma.com/role/Contingencies
24
false
false
All Reports
Book
All Reports
ctic-20200930.htm
ctic-20200930.xsd
ctic-20200930_cal.xml
ctic-20200930_def.xml
ctic-20200930_lab.xml
ctic-20200930_pre.xml
ex101ctibiopharmacorp2.htm
ex311-ceo302q3fy20.htm
ex312-cfo302q3fy20.htm
ex32-ceocfo906q3fy20.htm
http://fasb.org/us-gaap/2020-01-31
http://fasb.org/srt/2020-01-31
http://xbrl.sec.gov/dei/2020-01-31
true
true
JSON
41
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"instance": {
"ctic-20200930.htm": {
"axisCustom": 0,
"axisStandard": 13,
"contextCount": 116,
"dts": {
"calculationLink": {
"local": [
"ctic-20200930_cal.xml"
]
},
"definitionLink": {
"local": [
"ctic-20200930_def.xml"
],
"remote": [
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
"http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
]
},
"inline": {
"local": [
"ctic-20200930.htm"
]
},
"labelLink": {
"local": [
"ctic-20200930_lab.xml"
],
"remote": [
"https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
]
},
"presentationLink": {
"local": [
"ctic-20200930_pre.xml"
]
},
"referenceLink": {
"remote": [
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
"https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
]
},
"schema": {
"local": [
"ctic-20200930.xsd"
],
"remote": [
"http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
"http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
"http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
"https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
"https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
"http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
]
}
},
"elementCount": 262,
"entityCount": 1,
"hidden": {
"http://xbrl.sec.gov/dei/2020-01-31": 5,
"total": 5
},
"keyCustom": 16,
"keyStandard": 222,
"memberCustom": 7,
"memberStandard": 15,
"nsprefix": "ctic",
"nsuri": "http://www.ctibiopharma.com/20200930",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "0001001 - Document - Cover Page",
"role": "http://www.ctibiopharma.com/role/CoverPage",
"shortName": "Cover Page",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2109103 - Disclosure - Other Liabilities",
"role": "http://www.ctibiopharma.com/role/OtherLiabilities",
"shortName": "Other Liabilities",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2112104 - Disclosure - Equity Transactions",
"role": "http://www.ctibiopharma.com/role/EquityTransactions",
"shortName": "Equity Transactions",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2114105 - Disclosure - Related Party Transactions",
"role": "http://www.ctibiopharma.com/role/RelatedPartyTransactions",
"shortName": "Related Party Transactions",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LossContingencyDisclosures",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2116106 - Disclosure - Contingencies",
"role": "http://www.ctibiopharma.com/role/Contingencies",
"shortName": "Contingencies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LossContingencyDisclosures",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "ctic:DescriptionsOfBusinessPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2202201 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)",
"role": "http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies",
"shortName": "Description of Business and Summary of Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "ctic:DescriptionsOfBusinessPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2303301 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)",
"role": "http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
"shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"us-gaap:OtherAssetsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2307302 - Disclosure - Other Assets (Tables)",
"role": "http://www.ctibiopharma.com/role/OtherAssetsTables",
"shortName": "Other Assets (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:OtherAssetsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2310303 - Disclosure - Other Liabilities (Tables)",
"role": "http://www.ctibiopharma.com/role/OtherLiabilitiesTables",
"shortName": "Other Liabilities (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RetainedEarningsAccumulatedDeficit",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2404401 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)",
"role": "http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
"shortName": "Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"us-gaap:ValueAddedTaxReceivable",
"span",
"div",
"ctic:ValueAddedTaxPolicyTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:ValueAddedTaxReceivable",
"reportCount": 1,
"unique": true,
"unitRef": "eur",
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2405402 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Cash and Cash Equivalents and Short-term Investments Measured at Fair Value on a Recurring Basis (Details)",
"role": "http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails",
"shortName": "Description of Business and Summary of Significant Accounting Policies - Cash and Cash Equivalents and Short-term Investments Measured at Fair Value on a Recurring Basis (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
"role": "http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfOtherAssetsTableTextBlock",
"us-gaap:OtherAssetsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "ctic:OperatingLeaseRightOfUseAssetNoncurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2408403 - Disclosure - Other Assets (Details)",
"role": "http://www.ctibiopharma.com/role/OtherAssetsDetails",
"shortName": "Other Assets (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfOtherAssetsTableTextBlock",
"us-gaap:OtherAssetsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "ctic:OperatingLeaseRightOfUseAssetNoncurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:OtherLiabilitiesTableTextBlock",
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2411404 - Disclosure - Other Liabilities (Details)",
"role": "http://www.ctibiopharma.com/role/OtherLiabilitiesDetails",
"shortName": "Other Liabilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:OtherLiabilitiesTableTextBlock",
"us-gaap:OtherLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "if782b7d1618e4980b1fdcb1b448defe8_D20200301-20200331",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2413405 - Disclosure - Equity Transactions (Details)",
"role": "http://www.ctibiopharma.com/role/EquityTransactionsDetails",
"shortName": "Equity Transactions (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "if782b7d1618e4980b1fdcb1b448defe8_D20200301-20200331",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i50ff8c12822a43e0a16c4cba9e9d60ec_D20200701-20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherNonoperatingIncomeExpense",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2415406 - Disclosure - Related Party Transactions (Details)",
"role": "http://www.ctibiopharma.com/role/RelatedPartyTransactionsDetails",
"shortName": "Related Party Transactions (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "id8ef326896834be8a447a5f648ab0dcd_D20200101-20200930",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:OtherNonoperatingIncomeExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i5e7d65ccd01a4c69bc8343a1dec18622_I20200930",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
"reportCount": 1,
"unique": true,
"unitRef": "eur",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2417407 - Disclosure - Contingencies (Details)",
"role": "http://www.ctibiopharma.com/role/ContingenciesDetails",
"shortName": "Contingencies (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i5e7d65ccd01a4c69bc8343a1dec18622_I20200930",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
"reportCount": 1,
"unique": true,
"unitRef": "eur",
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unitRef": "usdPerShare",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
"role": "http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "ie29b23f8879b41b5a9eade5a058d4f95_I20200930",
"decimals": "INF",
"lang": "en-US",
"name": "us-gaap:PreferredStockSharesAuthorized",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i50ff8c12822a43e0a16c4cba9e9d60ec_D20200701-20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
"role": "http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i50ff8c12822a43e0a16c4cba9e9d60ec_D20200701-20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i50ff8c12822a43e0a16c4cba9e9d60ec_D20200701-20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:ProfitLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
"role": "http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i50ff8c12822a43e0a16c4cba9e9d60ec_D20200701-20200930",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "iec8c966a36e04bdeb4af69f92dbb59db_I20181231",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:SharesOutstanding",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
"role": "http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i5a253ab3c1ab415cadb86791341eab5f_D20190101-20190331",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:ProfitLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
"role": "http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:DepreciationAndAmortization",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2101101 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
"role": "http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
"shortName": "Description of Business and Summary of Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2106102 - Disclosure - Other Assets",
"role": "http://www.ctibiopharma.com/role/OtherAssets",
"shortName": "Other Assets",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "ctic-20200930.htm",
"contextRef": "i894b69eb08fd4031a3f1099f0739b60d_D20200101-20200930",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 22,
"tag": {
"ctic_AequusBiopharmaIncMember": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Aequus Biopharma, Inc",
"label": "Aequus Biopharma Inc [Member]",
"terseLabel": "Aequus Biopharma, Inc"
}
}
},
"localname": "AequusBiopharmaIncMember",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.ctibiopharma.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"ctic_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost": {
"auth_ref": [],
"calculation": {
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails_1": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Cash, Cash Equivalents, and Short-term Investments, Amortized Cost",
"label": "Cash, Cash Equivalents, and Short-term Investments, Amortized Cost",
"totalLabel": "Total cash, cash equivalents and short-term investments, amortized cost"
}
}
},
"localname": "CashCashEquivalentsAndShortTermInvestmentsAmortizedCost",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"ctic_CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAmortizedCost": {
"auth_ref": [],
"calculation": {
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails": {
"order": 2.0,
"parentTag": "ctic_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Cash, Cash Equivalents, and Short-term Investments, Gross Unrealized Gains, Amortized Cost",
"label": "Cash, Cash Equivalents, and Short-term Investments, Gross Unrealized Gains, Amortized Cost",
"totalLabel": "Total cash, cash equivalents and short-term investments, gross unrealized gains"
}
}
},
"localname": "CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGainsAmortizedCost",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"ctic_CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedLossesAmortizedCost": {
"auth_ref": [],
"calculation": {
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails": {
"order": 3.0,
"parentTag": "ctic_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Cash, Cash Equivalents, and Short-term Investments, Gross Unrealized Losses, Amortized Cost",
"label": "Cash, Cash Equivalents, and Short-term Investments, Gross Unrealized Losses, Amortized Cost",
"negatedTotalLabel": "Total cash, cash equivalents and short-term investments, gross unrealized losses"
}
}
},
"localname": "CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedLossesAmortizedCost",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"ctic_ClinicalTrialDepositsNoncurrent": {
"auth_ref": [],
"calculation": {
"http://www.ctibiopharma.com/role/OtherAssetsDetails": {
"order": 4.0,
"parentTag": "us-gaap_OtherAssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Clinical Trial Deposits, Noncurrent",
"label": "Clinical Trial Deposits, Noncurrent",
"terseLabel": "Clinical trial deposits"
}
}
},
"localname": "ClinicalTrialDepositsNoncurrent",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/OtherAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"ctic_ConvertiblePreferredStockMaximumSharesUponSettlement": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Convertible Preferred Stock, Maximum Shares Upon Settlement",
"label": "Convertible Preferred Stock, Maximum Shares Upon Settlement",
"terseLabel": "Shares available for future conversion (in shares)"
}
}
},
"localname": "ConvertiblePreferredStockMaximumSharesUponSettlement",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "sharesItemType"
},
"ctic_DescriptionOfBusinessAndSignificantAccountingPoliciesLineItems": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Description of business and significant accounting policies.",
"label": "Description Of Business And Significant Accounting Policies [Line Items]",
"terseLabel": "Description Of Business And Significant Accounting Policies [Line Items]"
}
}
},
"localname": "DescriptionOfBusinessAndSignificantAccountingPoliciesLineItems",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"ctic_DescriptionOfBusinessAndSignificantAccountingPoliciesTable": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Description of business and significant accounting policies.",
"label": "Description Of Business And Significant Accounting Policies [Table]",
"terseLabel": "Description Of Business And Significant Accounting Policies [Table]"
}
}
},
"localname": "DescriptionOfBusinessAndSignificantAccountingPoliciesTable",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"ctic_DescriptionsOfBusinessPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Descriptions of business policy.",
"label": "Descriptions Of Business [Policy Text Block]",
"terseLabel": "Description of Business"
}
}
},
"localname": "DescriptionsOfBusinessPolicyTextBlock",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"ctic_LimitationOnConvertibleSharesPercentOfOwnershipAsResultOfConversion": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Limitation On Convertible Shares, Percent Of Ownership As Result Of Conversion",
"label": "Limitation On Convertible Shares, Percent Of Ownership As Result Of Conversion",
"terseLabel": "Maximum ownership upon conversion"
}
}
},
"localname": "LimitationOnConvertibleSharesPercentOfOwnershipAsResultOfConversion",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "percentItemType"
},
"ctic_LiquidityDisclosurePolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Liquidity Disclosure [Policy Text Block]",
"label": "Liquidity Disclosure [Policy Text Block]",
"terseLabel": "Liquidity"
}
}
},
"localname": "LiquidityDisclosurePolicyTextBlock",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"ctic_LoanAndSecurityAgreementMember": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Loan And Security Agreement [Member]",
"label": "Loan And Security Agreement [Member]",
"terseLabel": "Loan and Security Agreement"
}
}
},
"localname": "LoanAndSecurityAgreementMember",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"ctic_OperatingLeaseRightOfUseAssetNoncurrent": {
"auth_ref": [],
"calculation": {
"http://www.ctibiopharma.com/role/OtherAssetsDetails": {
"order": 1.0,
"parentTag": "us-gaap_OtherAssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Operating Lease, Right-Of-Use Asset, Noncurrent",
"label": "Operating Lease, Right-Of-Use Asset, Noncurrent",
"terseLabel": "Right-of-use assets"
}
}
},
"localname": "OperatingLeaseRightOfUseAssetNoncurrent",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/OtherAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"ctic_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentIntercompanyBalanceNetOfTax": {
"auth_ref": [],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": 3.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Other Comprehensive Income (Loss), Foreign Currency Transaction And Translation Adjustment, Intercompany Balance, Net Of Tax",
"label": "Other Comprehensive Income (Loss), Foreign Currency Transaction And Translation Adjustment, Intercompany Balance, Net Of Tax",
"terseLabel": "Unrealized foreign exchange loss on intercompany balance"
}
}
},
"localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentIntercompanyBalanceNetOfTax",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
],
"xbrltype": "monetaryItemType"
},
"ctic_ProvisionForValueAddedTaxAssessments": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Provision for VAT assessments.",
"label": "Provision For Value Added Tax Assessments",
"terseLabel": "Provision for value added tax assessments"
}
}
},
"localname": "ProvisionForValueAddedTaxAssessments",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"ctic_RightsOfferingMember": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Rights Offering [Member]",
"label": "Rights Offering [Member]",
"terseLabel": "Rights Offering"
}
}
},
"localname": "RightsOfferingMember",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"ctic_SeriesOPreferredStockMember": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Series O Preferred Stock [Member]",
"label": "Series O Preferred Stock [Member]",
"terseLabel": "Series O Preferred Stock"
}
}
},
"localname": "SeriesOPreferredStockMember",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
],
"xbrltype": "domainItemType"
},
"ctic_SeriesXPreferredStockMember": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Series X Preferred Stock [Member]",
"label": "Series X Preferred Stock [Member]",
"terseLabel": "Series X Preferred Stock"
}
}
},
"localname": "SeriesXPreferredStockMember",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"ctic_SiliconValleyBankMember": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Silicon Valley Bank [Member]",
"label": "Silicon Valley Bank [Member]",
"terseLabel": "Silicon Valley Bank"
}
}
},
"localname": "SiliconValleyBankMember",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"ctic_StockIssuedDuringPeriodPreferredSharesIssuedReclassification": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Stock Issued During Period, Preferred Shares, Issued, Reclassification",
"label": "Stock Issued During Period, Preferred Shares, Issued, Reclassification",
"terseLabel": "Reclassification of Series X preferred stock from mezzanine equity (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodPreferredSharesIssuedReclassification",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "sharesItemType"
},
"ctic_StockIssuedDuringPeriodPreferredSharesValue.IssuedReclassification": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Stock Issued During Period, Preferred Shares, Value. Issued, Reclassification",
"label": "Stock Issued During Period, Preferred Shares, Value. Issued, Reclassification",
"terseLabel": "Reclassification of Series X preferred stock from mezzanine equity"
}
}
},
"localname": "StockIssuedDuringPeriodPreferredSharesValue.IssuedReclassification",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"ctic_ValueAddedTaxAssessmentsMember": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "VAT assessments.",
"label": "Value Added Tax Assessments [Member]",
"terseLabel": "VAT Assessments"
}
}
},
"localname": "ValueAddedTaxAssessmentsMember",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/ContingenciesDetails"
],
"xbrltype": "domainItemType"
},
"ctic_ValueAddedTaxPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Value added tax receivable policy.",
"label": "Value Added Tax [Policy Text Block]",
"terseLabel": "Italian Value Added Tax Receivable"
}
}
},
"localname": "ValueAddedTaxPolicyTextBlock",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"ctic_ValueAddedTaxPotentialPayment": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Value Added Tax Potential Payment",
"label": "Value Added Tax Potential Payment",
"terseLabel": "Potential payment to tax authority"
}
}
},
"localname": "ValueAddedTaxPotentialPayment",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"ctic_ValueAddedTaxReceivableDepositNoncurrent": {
"auth_ref": [],
"calculation": {
"http://www.ctibiopharma.com/role/OtherAssetsDetails": {
"order": 3.0,
"parentTag": "us-gaap_OtherAssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Value Added Tax Receivable, Deposit, Noncurrent",
"label": "Value Added Tax Receivable, Deposit, Noncurrent",
"terseLabel": "Italian VAT deposit, net"
}
}
},
"localname": "ValueAddedTaxReceivableDepositNoncurrent",
"nsuri": "http://www.ctibiopharma.com/20200930",
"presentation": [
"http://www.ctibiopharma.com/role/OtherAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]",
"terseLabel": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus",
"terseLabel": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r372"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report",
"terseLabel": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r373"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report",
"terseLabel": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine2": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Address Line 2 such as Street or Suite number",
"label": "Entity Address, Address Line Two",
"terseLabel": "Entity Address, Address Line Two"
}
}
},
"localname": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r374"
],
"lang": {
"en-US": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding",
"terseLabel": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status",
"terseLabel": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r374"
],
"lang": {
"en-US": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r374"
],
"lang": {
"en-US": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category",
"terseLabel": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r375"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current",
"terseLabel": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r374"
],
"lang": {
"en-US": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r374"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company",
"terseLabel": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r374"
],
"lang": {
"en-US": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business",
"terseLabel": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r374"
],
"lang": {
"en-US": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r371"
],
"lang": {
"en-US": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security",
"terseLabel": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "securityTitleItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CoverPage"
],
"xbrltype": "tradingSymbolItemType"
},
"srt_AffiliatedEntityMember": {
"auth_ref": [
"r219",
"r276",
"r277",
"r279",
"r370"
],
"lang": {
"en-US": {
"role": {
"label": "Affiliated Entity [Member]",
"terseLabel": "Affiliated Entity"
}
}
},
"localname": "AffiliatedEntityMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.ctibiopharma.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
"auth_ref": [
"r105",
"r110",
"r165",
"r226",
"r227",
"r228",
"r231",
"r232"
],
"lang": {
"en-US": {
"role": {
"label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
"terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
}
}
},
"localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"srt_CumulativeEffectPeriodOfAdoptionAxis": {
"auth_ref": [
"r105",
"r110",
"r165",
"r226",
"r227",
"r228",
"r231",
"r232"
],
"lang": {
"en-US": {
"role": {
"label": "Cumulative Effect, Period of Adoption [Axis]",
"terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
}
}
},
"localname": "CumulativeEffectPeriodOfAdoptionAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "stringItemType"
},
"srt_CumulativeEffectPeriodOfAdoptionDomain": {
"auth_ref": [
"r105",
"r110",
"r165",
"r226",
"r227",
"r228",
"r231",
"r232"
],
"lang": {
"en-US": {
"role": {
"label": "Cumulative Effect, Period of Adoption [Domain]",
"terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
}
}
},
"localname": "CumulativeEffectPeriodOfAdoptionDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"srt_OwnershipAxis": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Ownership [Axis]",
"terseLabel": "Ownership [Axis]"
}
}
},
"localname": "OwnershipAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.ctibiopharma.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"srt_OwnershipDomain": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Ownership [Domain]",
"terseLabel": "Ownership [Domain]"
}
}
},
"localname": "OwnershipDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.ctibiopharma.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"srt_RestatementAxis": {
"auth_ref": [
"r101",
"r102",
"r103",
"r104",
"r106",
"r107",
"r108",
"r109",
"r110",
"r112",
"r113",
"r114",
"r115",
"r116",
"r126",
"r166",
"r167",
"r229",
"r232",
"r359",
"r360",
"r361",
"r362",
"r363",
"r364",
"r365",
"r366",
"r367",
"r368"
],
"lang": {
"en-US": {
"role": {
"label": "Revision of Prior Period [Axis]",
"terseLabel": "Revision of Prior Period [Axis]"
}
}
},
"localname": "RestatementAxis",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"srt_RestatementDomain": {
"auth_ref": [
"r101",
"r102",
"r103",
"r104",
"r106",
"r107",
"r108",
"r109",
"r110",
"r112",
"r113",
"r114",
"r115",
"r116",
"r126",
"r166",
"r167",
"r229",
"r232",
"r359",
"r360",
"r361",
"r362",
"r363",
"r364",
"r365",
"r366",
"r367",
"r368"
],
"lang": {
"en-US": {
"role": {
"label": "Revision of Prior Period [Domain]",
"terseLabel": "Revision of Prior Period [Domain]"
}
}
},
"localname": "RestatementDomain",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
"auth_ref": [
"r108",
"r109",
"r112",
"r113",
"r115",
"r116"
],
"lang": {
"en-US": {
"role": {
"label": "Revision of Prior Period, Error Correction, Adjustment [Member]",
"terseLabel": "Revision of Prior Period, Error Correction, Adjustment"
}
}
},
"localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
"nsuri": "http://fasb.org/srt/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Accounting Policies [Abstract]",
"terseLabel": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r27"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable, Current",
"terseLabel": "Accounts payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedLiabilitiesCurrent": {
"auth_ref": [
"r31"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Liabilities, Current",
"terseLabel": "Accrued expenses"
}
}
},
"localname": "AccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r19",
"r49",
"r50",
"r51",
"r348",
"r364",
"r368"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
"label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
"terseLabel": "Unrealized loss from accumulated other comprehensive loss",
"verboseLabel": "Accumulated other comprehensive income"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r48",
"r51",
"r52",
"r101",
"r102",
"r104",
"r244",
"r359",
"r360"
],
"lang": {
"en-US": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "AOCI Attributable to Parent [Member]",
"terseLabel": "Accumulated Other Comprehensive Income"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalPaidInCapital": {
"auth_ref": [
"r17",
"r229"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
"label": "Additional Paid in Capital",
"terseLabel": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapital",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r101",
"r102",
"r104",
"r226",
"r227",
"r228"
],
"lang": {
"en-US": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-in Capital [Member]",
"terseLabel": "Additional Paid-in Capital"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
"auth_ref": [
"r86",
"r270"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 2.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
"label": "Amortization of Debt Issuance Costs and Discounts",
"negatedLabel": "Amortization of debt discount and issuance costs"
}
}
},
"localname": "AmortizationOfFinancingCostsAndDiscounts",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r124"
],
"lang": {
"en-US": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
"terseLabel": "Anti-dilutive securities excluded from computation of earnings per share (in shares)"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r97",
"r142",
"r145",
"r151",
"r164",
"r238",
"r245",
"r254",
"r325",
"r346"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "ASSETS"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r2",
"r3",
"r44",
"r97",
"r164",
"r238",
"r245",
"r254"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Assets, Current [Abstract]",
"terseLabel": "Current assets:"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "stringItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
"auth_ref": [
"r160"
],
"calculation": {
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails": {
"order": 2.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
"terseLabel": "Gross Unrealized Gains"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
"auth_ref": [
"r161"
],
"calculation": {
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails": {
"order": 1.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
"negatedTerseLabel": "Gross Unrealized Losses"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
"auth_ref": [
"r158",
"r174"
],
"calculation": {
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails_1": {
"order": 2.0,
"parentTag": "ctic_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale, Amortized Cost",
"totalLabel": "Cost or Amortized Cost"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Debt Securities, Available-for-sale [Abstract]",
"terseLabel": "Debt Securities, Available-for-sale [Abstract]"
}
}
},
"localname": "AvailableForSaleSecuritiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
"auth_ref": [
"r157",
"r159",
"r174",
"r333"
],
"calculation": {
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails": {
"order": 3.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale",
"terseLabel": "Total Estimated Fair Value"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtSecurities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis of Accounting, Policy [Policy Text Block]",
"terseLabel": "Basis of Presentation"
}
}
},
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
"auth_ref": [
"r100",
"r138"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
"label": "Business Description and Accounting Policies [Text Block]",
"terseLabel": "Description of Business and Summary of Significant Accounting Policies"
}
}
},
"localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r1",
"r25",
"r88"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
"auth_ref": [],
"calculation": {
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
"weight": 1.0
},
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails_1": {
"order": 1.0,
"parentTag": "ctic_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash and Cash Equivalents, Fair Value Disclosure",
"terseLabel": "Cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsAndShortTermInvestments": {
"auth_ref": [
"r25"
],
"calculation": {
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails": {
"order": 1.0,
"parentTag": "ctic_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
"label": "Cash, Cash Equivalents, and Short-term Investments",
"terseLabel": "Total cash, cash equivalents and short-term investments",
"totalLabel": "Total cash, cash equivalents and short-term investments"
}
}
},
"localname": "CashCashEquivalentsAndShortTermInvestments",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r81",
"r88",
"r93"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
"periodEndLabel": "Cash and cash equivalents at end of period",
"periodStartLabel": "Cash and cash equivalents at beginning of period"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r81",
"r259"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"totalLabel": "Net increase (decrease) in cash and cash equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ClassOfStockDomain": {
"auth_ref": [
"r95",
"r97",
"r117",
"r118",
"r119",
"r121",
"r123",
"r128",
"r129",
"r130",
"r164",
"r254"
],
"lang": {
"en-US": {
"role": {
"documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
"label": "Class of Stock [Domain]",
"terseLabel": "Class of Stock [Domain]"
}
}
},
"localname": "ClassOfStockDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfStockLineItems": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Class of Stock [Line Items]",
"terseLabel": "Class of Stock [Line Items]"
}
}
},
"localname": "ClassOfStockLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r37",
"r184",
"r334",
"r353"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments and Contingencies",
"terseLabel": "Commitments and contingencies"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Commitments and Contingencies Disclosure [Abstract]",
"terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r101",
"r102"
],
"lang": {
"en-US": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common Stock"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r16"
],
"lang": {
"en-US": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Common stock par value (in dollars per share)"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r16"
],
"lang": {
"en-US": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock, Shares Authorized",
"terseLabel": "Common stock authorized (in shares)"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r16"
],
"lang": {
"en-US": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock, Shares, Issued",
"terseLabel": "Common stock issued (in shares)"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r16",
"r200"
],
"lang": {
"en-US": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock, Shares, Outstanding",
"terseLabel": "Common stock outstanding (in shares)"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r16"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock, Value, Issued",
"terseLabel": "Common stock, $0.001 par value per share:"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r55",
"r57",
"r58",
"r65",
"r339",
"r358"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
"totalLabel": "Comprehensive loss attributable to CTI"
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
"auth_ref": [
"r55",
"r57",
"r64",
"r236",
"r237",
"r249",
"r338",
"r357"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": 2.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
"negatedLabel": "Comprehensive loss attributable to noncontrolling interest"
}
}
},
"localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
"auth_ref": [
"r55",
"r57",
"r63",
"r235",
"r249",
"r337",
"r356"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
"totalLabel": "Comprehensive loss"
}
}
},
"localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConsolidationPolicyTextBlock": {
"auth_ref": [
"r94",
"r240"
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
"label": "Consolidation, Policy [Policy Text Block]",
"terseLabel": "Principles of Consolidation"
}
}
},
"localname": "ConsolidationPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ConversionOfStockSharesConverted1": {
"auth_ref": [
"r90",
"r91",
"r92"
],
"lang": {
"en-US": {
"role": {
"documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
"label": "Conversion of Stock, Shares Converted",
"terseLabel": "Number of shares converted (in shares)"
}
}
},
"localname": "ConversionOfStockSharesConverted1",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
"auth_ref": [
"r14",
"r15",
"r201",
"r204"
],
"lang": {
"en-US": {
"role": {
"documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
"label": "Convertible Preferred Stock, Shares Issued upon Conversion",
"terseLabel": "Shares issued upon conversion of share (in shares)"
}
}
},
"localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance": {
"auth_ref": [
"r38"
],
"lang": {
"en-US": {
"role": {
"documentation": "Aggregate number of nonredeemable convertible preferred shares reserved for future issuance.",
"label": "Convertible Preferred Stock, Shares Reserved for Future Issuance",
"terseLabel": "Preferred stock eligible for conversion (in shares)"
}
}
},
"localname": "ConvertiblePreferredStockSharesReservedForFutureIssuance",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CorporateDebtSecuritiesMember": {
"auth_ref": [
"r212",
"r220",
"r369"
],
"lang": {
"en-US": {
"role": {
"documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
"label": "Corporate Debt Securities [Member]",
"terseLabel": "Corporate debt securities"
}
}
},
"localname": "CorporateDebtSecuritiesMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CostsAndExpenses": {
"auth_ref": [
"r67"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Total costs of sales and operating expenses for the period.",
"label": "Costs and Expenses",
"totalLabel": "Total operating costs and expenses"
}
}
},
"localname": "CostsAndExpenses",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostsAndExpensesAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Costs and Expenses [Abstract]",
"terseLabel": "Operating costs and expenses:"
}
}
},
"localname": "CostsAndExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "stringItemType"
},
"us-gaap_CreditFacilityAxis": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Axis]",
"terseLabel": "Credit Facility [Axis]"
}
}
},
"localname": "CreditFacilityAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CreditFacilityDomain": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Domain]",
"terseLabel": "Credit Facility [Domain]"
}
}
},
"localname": "CreditFacilityDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentAxis": {
"auth_ref": [
"r9",
"r11",
"r12",
"r326",
"r328",
"r344"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
"label": "Debt Instrument [Axis]",
"terseLabel": "Debt Instrument [Axis]"
}
}
},
"localname": "DebtInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentFeeAmount": {
"auth_ref": [
"r34"
],
"calculation": {
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails": {
"order": 3.0,
"parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
"label": "Debt Instrument, Fee Amount",
"terseLabel": "End-of-facility lender fee"
}
}
},
"localname": "DebtInstrumentFeeAmount",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentLineItems": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Debt Instrument [Line Items]",
"terseLabel": "Debt Instrument [Line Items]"
}
}
},
"localname": "DebtInstrumentLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentNameDomain": {
"auth_ref": [
"r35"
],
"lang": {
"en-US": {
"role": {
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
"label": "Debt Instrument, Name [Domain]",
"terseLabel": "Debt Instrument, Name [Domain]"
}
}
},
"localname": "DebtInstrumentNameDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentTable": {
"auth_ref": [
"r35",
"r99",
"r201",
"r205",
"r206",
"r207",
"r268",
"r269",
"r271",
"r343"
],
"lang": {
"en-US": {
"role": {
"documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Schedule of Long-term Debt Instruments [Table]",
"terseLabel": "Schedule of Long-term Debt Instruments [Table]"
}
}
},
"localname": "DebtInstrumentTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]",
"terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
}
}
},
"localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_DepositsAssetsNoncurrent": {
"auth_ref": [
"r26"
],
"calculation": {
"http://www.ctibiopharma.com/role/OtherAssetsDetails": {
"order": 5.0,
"parentTag": "us-gaap_OtherAssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
"label": "Deposits Assets, Noncurrent",
"terseLabel": "Refundable security deposit"
}
}
},
"localname": "DepositsAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DepreciationAndAmortization": {
"auth_ref": [
"r86",
"r179"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
"label": "Depreciation, Depletion and Amortization, Nonproduction",
"terseLabel": "Depreciation and amortization"
}
}
},
"localname": "DepreciationAndAmortization",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EarningsPerShareBasicAndDiluted": {
"auth_ref": [
"r122"
],
"lang": {
"en-US": {
"role": {
"documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share, Basic and Diluted",
"terseLabel": "Basic and diluted net loss per common share (in dollars per share)"
}
}
},
"localname": "EarningsPerShareBasicAndDiluted",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerSharePolicyTextBlock": {
"auth_ref": [
"r94",
"r124",
"r125"
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
"label": "Earnings Per Share, Policy [Policy Text Block]",
"terseLabel": "Net Loss per Share"
}
}
},
"localname": "EarningsPerSharePolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r259"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 4.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
"terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
}
}
},
"localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EquityAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Equity [Abstract]",
"terseLabel": "Equity [Abstract]"
}
}
},
"localname": "EquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r101",
"r102",
"r104",
"r107",
"r113",
"r116",
"r127",
"r165",
"r200",
"r208",
"r226",
"r227",
"r228",
"r231",
"r232",
"r260",
"r261",
"r262",
"r263",
"r264",
"r266",
"r359",
"r360",
"r361"
],
"lang": {
"en-US": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
"auth_ref": [
"r250",
"r251"
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
"terseLabel": "Summary of Cash and Cash Equivalents, Measured at Fair Value on a Recurring Basis"
}
}
},
"localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
"terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
}
}
},
"localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByBalanceSheetGroupingTable": {
"auth_ref": [
"r250",
"r252",
"r253"
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
"label": "Fair Value, by Balance Sheet Grouping [Table]",
"terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
}
}
},
"localname": "FairValueByBalanceSheetGroupingTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r218",
"r220",
"r251",
"r285",
"r286",
"r287"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value Hierarchy and NAV [Axis]",
"terseLabel": "Fair Value Hierarchy and NAV [Axis]"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r212",
"r213",
"r218",
"r220",
"r251",
"r285"
],
"lang": {
"en-US": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value, Inputs, Level 1 [Member]",
"terseLabel": "Level 1"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r212",
"r213",
"r218",
"r220",
"r251",
"r286"
],
"lang": {
"en-US": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value, Inputs, Level 2 [Member]",
"terseLabel": "Level 2"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
"label": "Fair Value Measurement, Policy [Policy Text Block]",
"terseLabel": "Cash, Cash Equivalents and Short-term Investments"
}
}
},
"localname": "FairValueMeasurementPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r218",
"r220",
"r285",
"r286",
"r287"
],
"lang": {
"en-US": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Hierarchy and NAV [Domain]",
"terseLabel": "Fair Value Hierarchy and NAV [Domain]"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FinancialInstrumentAxis": {
"auth_ref": [
"r162",
"r163",
"r168",
"r170",
"r171",
"r172",
"r173",
"r175",
"r176",
"r177",
"r178",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289",
"r290",
"r291",
"r292",
"r293",
"r294",
"r295",
"r296",
"r297",
"r298",
"r299",
"r300",
"r301",
"r302",
"r303",
"r304",
"r305",
"r306",
"r307",
"r308",
"r309",
"r310",
"r311"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by type of financial instrument.",
"label": "Financial Instrument [Axis]",
"terseLabel": "Financial Instrument [Axis]"
}
}
},
"localname": "FinancialInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
"auth_ref": [
"r255",
"r256",
"r257",
"r258"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 3.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
"label": "Foreign Currency Transaction Gain (Loss), before Tax",
"terseLabel": "Foreign exchange gain (loss)"
}
}
},
"localname": "ForeignCurrencyTransactionGainLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Income Statement [Abstract]",
"terseLabel": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Increase (Decrease) in Operating Capital [Abstract]",
"terseLabel": "Changes in operating assets and liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInOperatingLiabilities": {
"auth_ref": [
"r85"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 9.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.",
"label": "Increase (Decrease) in Operating Liabilities",
"terseLabel": "Accounts payable, accrued expenses and other liabilities"
}
}
},
"localname": "IncreaseDecreaseInOperatingLiabilities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"auth_ref": [
"r85"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
"label": "Increase (Decrease) in Prepaid Expense and Other Assets",
"negatedLabel": "Prepaid expenses and other assets"
}
}
},
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
"terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
}
}
},
"localname": "IncreaseDecreaseInStockholdersEquityRollForward",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "stringItemType"
},
"us-gaap_InterestExpense": {
"auth_ref": [
"r60",
"r141",
"r267",
"r270",
"r340"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 1.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
"label": "Interest Expense",
"negatedLabel": "Interest expense"
}
}
},
"localname": "InterestExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPaidNet": {
"auth_ref": [
"r79",
"r83",
"r89"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
"label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
"terseLabel": "Cash paid during the period for interest"
}
}
},
"localname": "InterestPaidNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentIncomeNet": {
"auth_ref": [
"r70",
"r72"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 4.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
"label": "Investment Income, Net",
"terseLabel": "Interest income"
}
}
},
"localname": "InvestmentIncomeNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeLeasesPolicyTextBlock": {
"auth_ref": [
"r273"
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
"label": "Lessee, Leases [Policy Text Block]",
"terseLabel": "Leases"
}
}
},
"localname": "LesseeLeasesPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r30",
"r97",
"r146",
"r164",
"r239",
"r245",
"r246",
"r254"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r22",
"r97",
"r164",
"r254",
"r330",
"r351"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities and Equity",
"totalLabel": "Total liabilities and stockholders' equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Liabilities and Equity [Abstract]",
"terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r33",
"r97",
"r164",
"r239",
"r245",
"r246",
"r254"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities, Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Liabilities, Current [Abstract]",
"terseLabel": "Current liabilities:"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityAxis": {
"auth_ref": [
"r28",
"r99"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
"label": "Lender Name [Axis]",
"terseLabel": "Lender Name [Axis]"
}
}
},
"localname": "LineOfCreditFacilityAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityLenderDomain": {
"auth_ref": [
"r28"
],
"lang": {
"en-US": {
"role": {
"documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
"label": "Line of Credit Facility, Lender [Domain]",
"terseLabel": "Line of Credit Facility, Lender [Domain]"
}
}
},
"localname": "LineOfCreditFacilityLenderDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LongTermDebtCurrent": {
"auth_ref": [
"r29"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
"label": "Long-term Debt, Current Maturities",
"terseLabel": "Current portion of long-term debt"
}
}
},
"localname": "LongTermDebtCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtNoncurrent": {
"auth_ref": [
"r35"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
"label": "Long-term Debt, Excluding Current Maturities",
"terseLabel": "Long-term debt, less current portion"
}
}
},
"localname": "LongTermDebtNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LossContingenciesByNatureOfContingencyAxis": {
"auth_ref": [
"r184",
"r185",
"r186",
"r188",
"r189",
"r190",
"r192",
"r195",
"r196"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
"label": "Loss Contingency Nature [Axis]",
"terseLabel": "Loss Contingencies By Nature Of Contingency"
}
}
},
"localname": "LossContingenciesByNatureOfContingencyAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/ContingenciesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LossContingenciesLineItems": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Loss Contingencies [Line Items]",
"terseLabel": "Loss Contingencies [Line Items]"
}
}
},
"localname": "LossContingenciesLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/ContingenciesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LossContingenciesTable": {
"auth_ref": [
"r184",
"r185",
"r186",
"r188",
"r189",
"r190",
"r192",
"r195",
"r196"
],
"lang": {
"en-US": {
"role": {
"documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
"label": "Loss Contingencies [Table]",
"terseLabel": "Loss Contingencies [Table]"
}
}
},
"localname": "LossContingenciesTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/ContingenciesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LossContingencyDisclosures": {
"auth_ref": [
"r193",
"r194"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.",
"label": "Contingencies Disclosure [Text Block]",
"terseLabel": "Contingencies"
}
}
},
"localname": "LossContingencyDisclosures",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/Contingencies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LossContingencyEstimateOfPossibleLoss": {
"auth_ref": [
"r187",
"r191",
"r195"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
"label": "Loss Contingency, Estimate of Possible Loss",
"terseLabel": "Range of possible loss"
}
}
},
"localname": "LossContingencyEstimateOfPossibleLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/ContingenciesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LossContingencyNatureDomain": {
"auth_ref": [
"r184",
"r185",
"r186",
"r188",
"r189",
"r190",
"r192",
"r195",
"r196"
],
"lang": {
"en-US": {
"role": {
"documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
"label": "Loss Contingency, Nature [Domain]",
"terseLabel": "Loss Contingency Nature"
}
}
},
"localname": "LossContingencyNatureDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/ContingenciesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_MinorityInterest": {
"auth_ref": [
"r42",
"r97",
"r164",
"r254",
"r329",
"r350"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
"label": "Stockholders' Equity Attributable to Noncontrolling Interest",
"terseLabel": "Noncontrolling interest"
}
}
},
"localname": "MinorityInterest",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MinorityInterestOwnershipPercentageByParent": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
"label": "Noncontrolling Interest, Ownership Percentage by Parent",
"terseLabel": "Interest in majority-owned subsidiary"
}
}
},
"localname": "MinorityInterestOwnershipPercentageByParent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_MinorityInterestPeriodIncreaseDecrease": {
"auth_ref": [
"r234"
],
"lang": {
"en-US": {
"role": {
"documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
"label": "Noncontrolling Interest, Period Increase (Decrease)",
"terseLabel": "Noncontrolling interest"
}
}
},
"localname": "MinorityInterestPeriodIncreaseDecrease",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MoneyMarketFundsMember": {
"auth_ref": [
"r212"
],
"lang": {
"en-US": {
"role": {
"documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
"label": "Money Market Funds [Member]",
"terseLabel": "Money market funds"
}
}
},
"localname": "MoneyMarketFundsMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r81"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Net cash provided by (used in) financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
"terseLabel": "Financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r81"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Net cash (used in) provided by investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
"terseLabel": "Investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r81",
"r84",
"r87"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities",
"totalLabel": "Net cash used in operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
"terseLabel": "Operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r0",
"r53",
"r56",
"r61",
"r87",
"r97",
"r106",
"r108",
"r109",
"r110",
"r111",
"r115",
"r116",
"r120",
"r142",
"r144",
"r147",
"r150",
"r152",
"r164",
"r254",
"r335",
"r354"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income (Loss) Attributable to Parent",
"terseLabel": "Net loss",
"totalLabel": "Net loss"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
"auth_ref": [
"r53",
"r56",
"r115",
"r116",
"r242",
"r248"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
"label": "Net Income (Loss) Attributable to Noncontrolling Interest",
"negatedLabel": "Noncontrolling interest"
}
}
},
"localname": "NetIncomeLossAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "Recently Adopted and Issued Accounting Standards"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NoncontrollingInterestMember": {
"auth_ref": [
"r101",
"r102",
"r104",
"r208",
"r233"
],
"lang": {
"en-US": {
"role": {
"documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
"label": "Noncontrolling Interest [Member]",
"terseLabel": "Noncontrolling Interest"
}
}
},
"localname": "NoncontrollingInterestMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"us-gaap_NonoperatingIncomeExpense": {
"auth_ref": [
"r71"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 2.0,
"parentTag": "us-gaap_ProfitLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
"label": "Nonoperating Income (Expense)",
"totalLabel": "Total non-operating expense, net"
}
}
},
"localname": "NonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NonoperatingIncomeExpenseAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Nonoperating Income (Expense) [Abstract]",
"terseLabel": "Non-operating income (expense):"
}
}
},
"localname": "NonoperatingIncomeExpenseAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r142",
"r144",
"r147",
"r150",
"r152"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 1.0,
"parentTag": "us-gaap_ProfitLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income (Loss)",
"totalLabel": "Loss from operations"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"auth_ref": [
"r272"
],
"calculation": {
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
"label": "Operating Lease, Liability, Noncurrent",
"terseLabel": "Lease liabilities, non-current"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsDisclosureTextBlock": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.",
"label": "Other Assets Disclosure [Text Block]",
"terseLabel": "Other Assets"
}
}
},
"localname": "OtherAssetsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherAssets"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherAssetsMiscellaneous": {
"auth_ref": [],
"calculation": {
"http://www.ctibiopharma.com/role/OtherAssetsDetails": {
"order": 6.0,
"parentTag": "us-gaap_OtherAssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of other miscellaneous assets.",
"label": "Other Assets, Miscellaneous",
"terseLabel": "Other"
}
}
},
"localname": "OtherAssetsMiscellaneous",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r26"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
},
"http://www.ctibiopharma.com/role/OtherAssetsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other Assets, Noncurrent",
"terseLabel": "Other assets",
"totalLabel": "Other assets"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.ctibiopharma.com/role/OtherAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
"auth_ref": [
"r46",
"r47",
"r49"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": 2.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
"label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
"terseLabel": "Net unrealized gain (loss) on available-for-sale securities"
}
}
},
"localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
"auth_ref": [
"r45"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": 1.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
"label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
"terseLabel": "Foreign currency translation adjustments"
}
}
},
"localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r54",
"r57",
"r59",
"r62",
"r200",
"r260",
"r265",
"r266",
"r336",
"r355"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": 2.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
"label": "Other Comprehensive Income (Loss), Net of Tax",
"totalLabel": "Other comprehensive income (loss)",
"verboseLabel": "Other comprehensive income"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
"terseLabel": "Other comprehensive income (loss):"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherCostAndExpenseOperating": {
"auth_ref": [
"r68"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 4.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
"label": "Other Cost and Expense, Operating",
"terseLabel": "Other operating expenses"
}
}
},
"localname": "OtherCostAndExpenseOperating",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilitiesCurrent": {
"auth_ref": [
"r4",
"r5",
"r31"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Current",
"terseLabel": "Other current liabilities"
}
}
},
"localname": "OtherLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilitiesDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Other Liabilities Disclosure [Abstract]",
"terseLabel": "Other Liabilities Disclosure [Abstract]"
}
}
},
"localname": "OtherLiabilitiesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_OtherLiabilitiesDisclosureTextBlock": {
"auth_ref": [
"r32"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for other liabilities.",
"label": "Other Liabilities Disclosure [Text Block]",
"terseLabel": "Other Liabilities"
}
}
},
"localname": "OtherLiabilitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilities"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherLiabilitiesNoncurrent": {
"auth_ref": [
"r36"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
},
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Noncurrent",
"terseLabel": "Other liabilities",
"totalLabel": "Total other liabilities"
}
}
},
"localname": "OtherLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilitiesTableTextBlock": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of other liabilities.",
"label": "Other Liabilities [Table Text Block]",
"terseLabel": "Components of Other Liabilities"
}
}
},
"localname": "OtherLiabilitiesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherNoncashIncomeExpense": {
"auth_ref": [
"r87"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
"label": "Other Noncash Income (Expense)",
"negatedTerseLabel": "Other"
}
}
},
"localname": "OtherNoncashIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r73"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
},
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 5.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income (Expense)",
"negatedTerseLabel": "Loss on dissolution of majority-owned subsidiary",
"verboseLabel": "Loss on dissolution of majority-owned subsidiary"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.ctibiopharma.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherSundryLiabilities": {
"auth_ref": [
"r11",
"r13",
"r327",
"r347"
],
"calculation": {
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The aggregate carrying amount, as of the balance sheets date, of obligations not otherwise itemized or categorized in the footnotes to the financial statements.",
"label": "Other Sundry Liabilities",
"terseLabel": "Other long-term obligations"
}
}
},
"localname": "OtherSundryLiabilities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsOfStockIssuanceCosts": {
"auth_ref": [
"r78"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
"label": "Payments of Stock Issuance Costs",
"negatedTerseLabel": "Cash paid for at-the-market equity offering costs",
"terseLabel": "Offering costs"
}
}
},
"localname": "PaymentsOfStockIssuanceCosts",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireShortTermInvestments": {
"auth_ref": [
"r75"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
"label": "Payments to Acquire Short-term Investments",
"negatedTerseLabel": "Purchases of short-term investments"
}
}
},
"localname": "PaymentsToAcquireShortTermInvestments",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockLiquidationPreferenceValue": {
"auth_ref": [
"r95"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
"label": "Preferred Stock, Liquidation Preference, Value",
"terseLabel": "Preferred stock liquidation preference"
}
}
},
"localname": "PreferredStockLiquidationPreferenceValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockMember": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
"label": "Preferred Stock [Member]",
"terseLabel": "Preferred Stock"
}
}
},
"localname": "PreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r15"
],
"lang": {
"en-US": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Preferred Stock, Par or Stated Value Per Share",
"terseLabel": "Preferred stock par value (in dollars per share)",
"verboseLabel": "Preferred stock stated value (in dollars per share)"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r15"
],
"lang": {
"en-US": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred Stock, Shares Authorized",
"terseLabel": "Preferred stock authorized (in shares)"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r15"
],
"lang": {
"en-US": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred Stock, Shares Issued",
"terseLabel": "Preferred stock issued (in shares)"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r15"
],
"lang": {
"en-US": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred Stock, Shares Outstanding",
"terseLabel": "Preferred stock outstanding (in shares)"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r15"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 5.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Preferred Stock, Value, Issued",
"terseLabel": "Preferred stock, $0.001 par value per share:"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
"auth_ref": [
"r2",
"r23",
"r24"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
"label": "Prepaid Expense and Other Assets, Current",
"terseLabel": "Prepaid expenses and other current assets"
}
}
},
"localname": "PrepaidExpenseAndOtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromCollaborators": {
"auth_ref": [
"r82"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Cash received from collaborators during the current period.",
"label": "Proceeds from Collaborators",
"terseLabel": "Receivables from license and development services arrangements"
}
}
},
"localname": "ProceedsFromCollaborators",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfCommonStock": {
"auth_ref": [
"r76"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The cash inflow from the additional capital contribution to the entity.",
"label": "Proceeds from Issuance of Common Stock",
"terseLabel": "Proceeds from rights offering, net of issuance costs"
}
}
},
"localname": "ProceedsFromIssuanceOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
"auth_ref": [
"r76"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
"label": "Proceeds from Issuance or Sale of Equity",
"verboseLabel": "Proceeds from common stock offering"
}
}
},
"localname": "ProceedsFromIssuanceOrSaleOfEquity",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
"auth_ref": [
"r74",
"r75"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
"label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments",
"terseLabel": "Proceeds from maturities of short-term investments"
}
}
},
"localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromStockOptionsExercised": {
"auth_ref": [
"r76",
"r225"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
"label": "Proceeds from Stock Options Exercised",
"terseLabel": "Proceeds from stock option exercises"
}
}
},
"localname": "ProceedsFromStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromStockPlans": {
"auth_ref": [
"r76"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
"label": "Proceeds from Stock Plans",
"terseLabel": "Proceeds from sales of common stock under employee stock purchase plan"
}
}
},
"localname": "ProceedsFromStockPlans",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProfitLoss": {
"auth_ref": [
"r0",
"r53",
"r56",
"r80",
"r97",
"r106",
"r115",
"r116",
"r142",
"r144",
"r147",
"r150",
"r152",
"r164",
"r235",
"r241",
"r243",
"r248",
"r249",
"r254",
"r341"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
},
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
"label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
"terseLabel": "Net loss before noncontrolling interest",
"totalLabel": "Net loss before noncontrolling interest",
"verboseLabel": "Net loss before noncontrolling interest"
}
}
},
"localname": "ProfitLoss",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r6",
"r7",
"r180",
"r352"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Net",
"terseLabel": "Property and equipment, net"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProvisionForDoubtfulAccounts": {
"auth_ref": [
"r66",
"r169"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
"label": "Accounts Receivable, Credit Loss Expense (Reversal)",
"terseLabel": "Provision for Italian VAT receivables and deposit"
}
}
},
"localname": "ProvisionForDoubtfulAccounts",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RelatedPartyDomain": {
"auth_ref": [
"r219",
"r276",
"r277"
],
"lang": {
"en-US": {
"role": {
"documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
"label": "Related Party [Domain]",
"terseLabel": "Related Party [Domain]"
}
}
},
"localname": "RelatedPartyDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.ctibiopharma.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RelatedPartyTransactionLineItems": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Related Party Transaction [Line Items]",
"terseLabel": "Related Party Transaction [Line Items]"
}
}
},
"localname": "RelatedPartyTransactionLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionsAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Related Party Transactions [Abstract]",
"terseLabel": "Related Party Transactions [Abstract]"
}
}
},
"localname": "RelatedPartyTransactionsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
"auth_ref": [
"r219",
"r276",
"r279",
"r313",
"r314",
"r315",
"r316",
"r317",
"r318",
"r319",
"r320",
"r321",
"r322",
"r323",
"r324"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
"label": "Related Party [Axis]",
"terseLabel": "Related Party [Axis]"
}
}
},
"localname": "RelatedPartyTransactionsByRelatedPartyAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.ctibiopharma.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
"auth_ref": [
"r274",
"r275",
"r277",
"r280",
"r281"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
"label": "Related Party Transactions Disclosure [Text Block]",
"terseLabel": "Related Party Transactions"
}
}
},
"localname": "RelatedPartyTransactionsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/RelatedPartyTransactions"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RepaymentsOfLongTermDebt": {
"auth_ref": [
"r77"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
"label": "Repayments of Long-term Debt",
"negatedLabel": "Principal payments on debt"
}
}
},
"localname": "RepaymentsOfLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
"auth_ref": [
"r230"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 1.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
"label": "Research and Development Expense (Excluding Acquired in Process Cost)",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringCharges": {
"auth_ref": [
"r86",
"r181",
"r182",
"r183"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 3.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
"label": "Restructuring Charges",
"terseLabel": "Restructuring expenses"
}
}
},
"localname": "RestructuringCharges",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r18",
"r208",
"r229",
"r349",
"r363",
"r368"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings (Accumulated Deficit)",
"negatedTerseLabel": "Accumulated deficit",
"terseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r101",
"r102",
"r104",
"r107",
"r113",
"r116",
"r165",
"r226",
"r227",
"r228",
"r231",
"r232",
"r359",
"r361"
],
"lang": {
"en-US": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]",
"terseLabel": "Accumulated Deficit"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
"auth_ref": [
"r139",
"r140",
"r143",
"r148",
"r149",
"r153",
"r154",
"r155",
"r210",
"r211",
"r312"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
"label": "Revenue from Contract with Customer, Excluding Assessed Tax",
"terseLabel": "License and contract revenues"
}
}
},
"localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SaleOfStockNameOfTransactionDomain": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
"label": "Sale of Stock [Domain]",
"terseLabel": "Sale of Stock [Domain]"
}
}
},
"localname": "SaleOfStockNameOfTransactionDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
"label": "Schedule of Other Assets [Table Text Block]",
"terseLabel": "Schedule of Other Assets"
}
}
},
"localname": "ScheduleOfOtherAssetsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherAssetsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
"auth_ref": [
"r98",
"r278",
"r279"
],
"lang": {
"en-US": {
"role": {
"documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
"label": "Schedule of Related Party Transactions, by Related Party [Table]",
"terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
}
}
},
"localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfStockByClassTable": {
"auth_ref": [
"r39",
"r95",
"r128",
"r129",
"r197",
"r198",
"r199",
"r201",
"r202",
"r203",
"r205",
"r206",
"r207",
"r208"
],
"lang": {
"en-US": {
"role": {
"documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
"label": "Schedule of Stock by Class [Table]",
"terseLabel": "Schedule of Stock by Class [Table]"
}
}
},
"localname": "ScheduleOfStockByClassTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SecuredDebtMember": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
"label": "Secured Debt [Member]",
"terseLabel": "Secured Debt"
}
}
},
"localname": "SecuredDebtMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpense": {
"auth_ref": [
"r69"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"order": 2.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
"label": "Selling, General and Administrative Expense",
"terseLabel": "General and administrative"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r85"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share-based Payment Arrangement, Noncash Expense",
"terseLabel": "Equity-based compensation"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
"auth_ref": [
"r94",
"r222",
"r223"
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
"label": "Share-based Payment Arrangement [Policy Text Block]",
"terseLabel": "Equity-based Compensation"
}
}
},
"localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SharesOutstanding": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
"label": "Shares, Outstanding",
"periodEndLabel": "Ending Balance (in shares)",
"periodStartLabel": "Beginning Balance (in shares)"
}
}
},
"localname": "SharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShortTermInvestments": {
"auth_ref": [
"r10",
"r331",
"r332",
"r345"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
"label": "Short-term Investments",
"terseLabel": "Short-term investments"
}
}
},
"localname": "ShortTermInvestments",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StatementClassOfStockAxis": {
"auth_ref": [
"r14",
"r15",
"r16",
"r95",
"r97",
"r117",
"r118",
"r119",
"r121",
"r123",
"r128",
"r129",
"r130",
"r164",
"r200",
"r254"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by the different classes of stock of the entity.",
"label": "Class of Stock [Axis]",
"terseLabel": "Class of Stock [Axis]"
}
}
},
"localname": "StatementClassOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r41",
"r101",
"r102",
"r104",
"r107",
"r113",
"r116",
"r127",
"r165",
"r200",
"r208",
"r226",
"r227",
"r228",
"r231",
"r232",
"r260",
"r261",
"r262",
"r263",
"r264",
"r266",
"r359",
"r360",
"r361"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]",
"terseLabel": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]",
"terseLabel": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Statement of Cash Flows [Abstract]",
"terseLabel": "Statement of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Statement of Financial Position [Abstract]",
"terseLabel": "Statement of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Statement of Comprehensive Income [Abstract]",
"terseLabel": "Statement of Comprehensive Income [Abstract]"
}
}
},
"localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]",
"terseLabel": "Statement of Stockholders' Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r101",
"r102",
"r104",
"r127",
"r312"
],
"lang": {
"en-US": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]",
"terseLabel": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
"auth_ref": [
"r40",
"r200",
"r201",
"r208"
],
"lang": {
"en-US": {
"role": {
"documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
"label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
"terseLabel": "Conversion of Series X preferred stock to common stock (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
"auth_ref": [
"r15",
"r16",
"r200",
"r208"
],
"lang": {
"en-US": {
"role": {
"documentation": "Number of new stock issued during the period.",
"label": "Stock Issued During Period, Shares, New Issues",
"terseLabel": "Shares issued (in shares)",
"verboseLabel": "Issuance of common stock, net of issuance costs (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesNewIssues",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
"auth_ref": [
"r15",
"r16",
"r200",
"r208"
],
"lang": {
"en-US": {
"role": {
"documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
"label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
"terseLabel": "Equity-based compensation (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
"auth_ref": [
"r41",
"r200",
"r208"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
"label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
"terseLabel": "Conversion of Series X preferred stock to common stock"
}
}
},
"localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueNewIssues": {
"auth_ref": [
"r15",
"r16",
"r200",
"r208"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
"label": "Stock Issued During Period, Value, New Issues",
"verboseLabel": "Issuance of common stock, net of issuance costs"
}
}
},
"localname": "StockIssuedDuringPeriodValueNewIssues",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
"auth_ref": [
"r15",
"r16",
"r208",
"r221",
"r224"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
"label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
"terseLabel": "Equity-based compensation"
}
}
},
"localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r16",
"r20",
"r21",
"r97",
"r156",
"r164",
"r254"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "Stockholders' Equity Attributable to Parent",
"totalLabel": "Total CTI stockholders' equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
"auth_ref": [
"r97",
"r101",
"r102",
"r104",
"r107",
"r113",
"r164",
"r165",
"r208",
"r226",
"r227",
"r228",
"r231",
"r232",
"r233",
"r234",
"r247",
"r254",
"r260",
"r261",
"r266",
"r360",
"r361"
],
"calculation": {
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
"label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
"periodEndLabel": "Ending Balance",
"periodStartLabel": "Beginning Balance",
"totalLabel": "Total stockholders' equity"
}
}
},
"localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
"terseLabel": "Stockholders' equity:"
}
}
},
"localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r96",
"r208",
"r209"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
"label": "Stockholders' Equity Note Disclosure [Text Block]",
"terseLabel": "Equity Transactions"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactions"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StockholdersEquityOther": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
"label": "Stockholders' Equity, Other",
"negatedLabel": "Other"
}
}
},
"localname": "StockholdersEquityOther",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityOtherShares": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Number of increase (decrease) in shares of stock classified as other.",
"label": "Stockholders' Equity, Other Shares",
"terseLabel": "Other (in shares)"
}
}
},
"localname": "StockholdersEquityOtherShares",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockholdersEquityPeriodIncreaseDecrease": {
"auth_ref": [
"r200",
"r208"
],
"lang": {
"en-US": {
"role": {
"documentation": "The increase (decrease) in stockholders' equity during the period.",
"label": "Stockholders' Equity, Period Increase (Decrease)",
"verboseLabel": "Dissolution of majority-owned subsidiary"
}
}
},
"localname": "StockholdersEquityPeriodIncreaseDecrease",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SubsidiarySaleOfStockAxis": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Information by type of sale of the entity's stock.",
"label": "Sale of Stock [Axis]",
"terseLabel": "Sale of Stock [Axis]"
}
}
},
"localname": "SubsidiarySaleOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/EquityTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SupplementalCashFlowInformationAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"label": "Supplemental Cash Flow Information [Abstract]",
"terseLabel": "Supplemental disclosure of cash flow information"
}
}
},
"localname": "SupplementalCashFlowInformationAbstract",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
],
"xbrltype": "stringItemType"
},
"us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
"auth_ref": [
"r162",
"r163",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289",
"r290",
"r291",
"r292",
"r293",
"r294",
"r295",
"r296",
"r297",
"r298",
"r299",
"r300",
"r301",
"r302",
"r303",
"r304",
"r305",
"r306",
"r307",
"r308",
"r309",
"r310",
"r311"
],
"lang": {
"en-US": {
"role": {
"documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
"label": "Financial Instruments [Domain]",
"terseLabel": "Financial Instruments [Domain]"
}
}
},
"localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_USGovernmentDebtSecuritiesMember": {
"auth_ref": [
"r342"
],
"lang": {
"en-US": {
"role": {
"documentation": "Debt securities issued by the United States government.",
"label": "US Government Debt Securities [Member]",
"terseLabel": "U.S. government and agency securities"
}
}
},
"localname": "USGovernmentDebtSecuritiesMember",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesCashandCashEquivalentsandShorttermInvestmentsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_UseOfEstimates": {
"auth_ref": [
"r131",
"r132",
"r133",
"r134",
"r135",
"r136",
"r137"
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
"label": "Use of Estimates, Policy [Policy Text Block]",
"terseLabel": "Use of Estimates"
}
}
},
"localname": "UseOfEstimates",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ValueAddedTaxReceivable": {
"auth_ref": [
"r43"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.",
"label": "Value Added Tax Receivable",
"terseLabel": "VAT receivable"
}
}
},
"localname": "ValueAddedTaxReceivable",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ValueAddedTaxReceivableNoncurrent": {
"auth_ref": [
"r8"
],
"calculation": {
"http://www.ctibiopharma.com/role/OtherAssetsDetails": {
"order": 2.0,
"parentTag": "us-gaap_OtherAssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle), if longer of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.",
"label": "Value Added Tax Receivable, Noncurrent",
"terseLabel": "Italian VAT receivables, net"
}
}
},
"localname": "ValueAddedTaxReceivableNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/OtherAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
"label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
"terseLabel": "Shares used in calculation of basic and diluted net loss per common share (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
"nsuri": "http://fasb.org/us-gaap/2020-01-31",
"presentation": [
"http://www.ctibiopharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
],
"xbrltype": "sharesItemType"
}
},
"unitCount": 5
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(2))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r100": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "http://asc.fasb.org/topic&trid=2122369"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "27",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "55",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(24))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
},
"r138": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "275",
"URI": "http://asc.fasb.org/topic&trid=2134479"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(aa)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "5A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(3)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(4)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.3)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(b))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(4))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r193": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/subtopic&trid=2127163"
},
"r194": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "30",
"Topic": "450",
"URI": "http://asc.fasb.org/subtopic&trid=2127197"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "460",
"URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "460",
"URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(CFRR 211.02)",
"Topic": "480",
"URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r209": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "http://asc.fasb.org/topic&trid=2208762"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(n)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b),(f)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "2A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(g)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(7))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(8))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "4I",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "4J",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "4K",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.1)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.17)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(b),22(b))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
},
"r281": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "850",
"URI": "http://asc.fasb.org/topic&trid=2122745"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)(i)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)(ii)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19,20)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(4)(i)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(4)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(5)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(6)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(7)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(b)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(a)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(b)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(a)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(b)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(a)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(b)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "33",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(a)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20,24)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "33",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(b)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "35A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(a)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "35A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(b)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(c)(1)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(c)(2)",
"Topic": "932",
"URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(13))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(15))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(22))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(4))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(5))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(6))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(23))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(24))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(25))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(26))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(b))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04.9)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "320",
"Subparagraph": "(b)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "470",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(16))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(1)(g))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(15))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(24))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(19))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(20))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(21))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(22))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.24)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(1)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iii)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iv)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(1)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 4))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r371": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r372": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r373": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r374": {
"Name": "Regulation 12B",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r375": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.28)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.28,29)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-30)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.31)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.8)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.9)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "17B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(13))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(210.5-03(11))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(21))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(22))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(23))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(24))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(5))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.3)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(14))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7(a),(b))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.8)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(d))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(k))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08.(e),(f))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
}
},
"version": "2.1"
}
ZIP
42
0000891293-20-000058-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0000891293-20-000058-xbrl.zip
M4$L#!!0 ( #B(:E%T5+(#K^4! +N2$@ 1 8W1I8RTR,#(P,#DS,"YH
M=&WLO6E7&\FR+OS]_@J]G//>T[T6:><\T-W<13-XT]<2-LAFPQ>O'$&@@:W!
M!G[]C2P),QC;#$*3J\_96%)5965F1#PQ9&3DG__GO-6L?([=7J/3_FN)O,)+
ME?^S^N?_A]"__]Y]6]GH^$$KMON5]6ZT_1@J7QK]X\I^B+W32NIV6I7]3O>T
M\=DB5#RSWCF[Z#:.COL5BBF^<[&[HJ5441J,>!(*<0J?3-0:)681,-TY-S89&B,
MS/'\VN,^C Y&V.ZM-,[_6CKN]\]67K_^\N7+JW/7;;[J=(]>4TS8ZT:[V6C'
M/.2ET>V^W_"W'H ?7*-S=FR[+?O*=UJO\Q"Q8?CJ"6CA]'NOP.QUONQL+U[=
MGJ^&QM<';MXL7P\O7MT:XIW[>M&_.NI\?@T7BFX@3! C-UMN_* GC7:O;]O^
M:T\&/71D[=G7)Y+MN>+NT85[7M$X[R/HQ*V77'7J>BY?][NVW4L=F+$^L%>>
M:H&POMG5WNV.?F%7W22O_UU]N^>/8\NBNQUN]#J<$O6C(0[OUPWRN(,>;U
M>>:/JU9[W?ZW4P _WC?#W]#Z5JOYZHV9NK^?/YLFBJ@L&EEIVO;17TNQC3[L
M+0%+1QM6_VS%OJWD9E'\SZ#Q^:^E]4Z[#X**ZA=G,$]^^.VOI7X\[[\N1OEZ
M]7_]K__U9[_1;\;5S-SHBG__?#W\\<_7PZ9=)URL_AD:GRN]_D4S_K44&KVS
MIKU8:7?:$3K0.%_)-\;N\&,CA-@N/L+U&J!%M^&'[S_O[\;TUU)#&^ZDB0[K
M%#AFQ+)$L#$)*V:GN'KYX;)V^7>CNK%[?)#5DW]:M9/0K%X>\%H]P/.'
MS6IK4^S4_<7AQGMV"/7'X@AV_>CY[Y".\2[<-ZYZ+:.J U"N,Z.2(U^A[7
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MR9OML $V?TGAGU&8W*0PCX(9"W.
MN[[VM9OAQJT&98OY]I6K[U7UKHJ[:&;0;PTGK@0\9>U^GH15M;]"-JZ/7
M%Q>OFKBZ=O4]MW$O'8AVE@0MA;*")VP<4$%38B40PT0J/VWG[A."V0Q,_]"?
MZP]GE,#D7S*$-=GA$18+
M'7@R8CB;,\+,MV;S%G\^;C9O\Q.Q@L*0*7 5#P+K2(2FAN-HI538Y!D@T&OP
MB6=I!HBY M;G\A.8KGM9%+\.#QQBZ-;-6PO4MOU.]XFL]\WS^<>-V.ZT&NW[
MFGTH0-QJXO7MWO^,\T.P. 4ML,? ^5Q8SIF,W G.E7"*38[NH]'&H^Q.#+\&
M>-GY6;/A&_UJ;#EX16C U6'H-H;@^;.[/U_>^Y>NL?>W,!'GR-BY)3U4"\:-*1P:6&H,T;,Q#Y%S(#>GH'8"*+S)\44^&M:>!T6A3K_GDOJ$""$
M3YXXKA4/5H/!2D1BT7$P5(G5BX)L$Z3.&)%-X)2T)U13:CF+V!+IN7=@>)D@
M0C/T+-MA^A)N%'W)HW'XR1C$KF->7$*P>V6G#$).DT<4GG>2-F-&_P8?;F
M#9CHH?.6;QW3O 5-(XD$W'$3N7;@/+G(/&,X*BI]#*-Y([,];P_T6\1X9J=UUFG#U]X02:]NFTL43<08
M03E6U@;. KC_DL$DI@ ?C8J+0QWXO=5ISQ-I',:"&0-&AR/<$JR3%F#!<\>H
M(-BFA2'-6@B-O(QMF^]L(VRWU^U9HV^;\T*FQ((3(H1H$P\X6IVL$DPYH[7'
M."P.F;P?M ;-G-2STS^.W7Q?-Q[GUC['[;;OM.*\D"R0*+PBT8!D!>; ?L16
MFX2M$02=F>4R?
MN%QXDJB++H"A+Y2RE":+K7,F,F7]-*1U/N;-"4DDF. I&!]_HDYV< [&Y-]KAT'
ML$K6N\B)B"9$P2CF0IB07' +0YT)!27&2!HOG>/*82Z5 -/<6>RE"V\&3DL_,IAD7.07#)=&_>NN\(?[J[(\:RALLRP,0'T1,>Q(3IY
M'[UPC!@?A:2+1].I168F3]P0C171 DYQR5URVB@2"&8^, S6FYP"<>=BWBCW
M@'":4QHMQ]%H8ZWGBGI0T$%]W4BP0$(Q*4Z!!!VPT6SR"3CZ,.@6JFB09
M%98S%;AB5E,*UHFP8&UJ)X9[/A:"F),-H\KQY"\'C[$78!\*[3FWT=!$J;:$
MQ4@HD8M#G0F&4<=$FF2\S#G_2B3#J06#WFAOHZ-2D41#6!C23"F,.B8R40XV
MAY+!22RXP=$R,$2BIM%;:7U,BT.FZ8=1QR59DF(KI3>!8\[!X @6' .E'*?>
MA1 7AF23#J..B3X ;UI&IT2@EAL@D,&$4B&L$RPFLCC(-YTPZIBH9$((/C%E
MDC?<>^N4L$48"B=R:
M8*W&+DK%0J3!,KUX5)V*V39]0FM/$Z:1>P*JR#H+QK@*02=A\&BV*.MDW/
M4MAA3-NFF9#,,!48 "D'F=1)!0G.K?))4#+,WE\(ZDPP[# NTC@I<<[6(HSQ
M))-ES(OHG3 <%&%0"T.:*84=QD2F!/+"C*<$C-"\(@@V">?@R1(JJ,/#DBJ+
M0:;IAQW&52M"'9),..XR)/LH:@X6U5G&>
MM] ZF[PB1$5/O6!QGBJMS&+884Q4BEY[(Z5E,F+N0G3<)FF2H<&!CAHF?A.]
M !O_)E@K0(]MPY\!:#/88T5% .I@FP+Q5MCD4E!<^H6ASJ1J!8R/-& M).<-
M9H13KAFV8'#;F'-5N5*2A84AS31J!8Q1@B+XJ-&XD"+E>8$<<^.#SR(5M$]J
M<<@TY5H!XR,9P9Y[$CRV8#> 0UO4P8]6&4DL&!6+HY(F6BM@?/21E/@$0B23
MM!SHH<&".1Q_ M),J:D89FQR5
MIC4#GDJ3HU\\.B?]J+7[:^L#W4*J)#-E*+O
M#P^+V$EKH7.67SGLR(/N#">#7C\/9DX$* BK*.&:)&:X=E8[09+%)B5&751R
M=MEG2H0KU>,0=H0V@F)GG(F<*FHD<(M30C&!N6"TY)L9)1R5WG/GO0TA<^4Y=0Y<"$9ER!D'
M,N!A(9'%(NA4$DJF1%Q+!;..>6(=)P*DUFFI#&&<1.M$F@)QYV/> -,P(%HP
M07%!M091P,E'9Y)@6)C%$XK))N),AZHVZLEM8M'
MU:DGXDR'T-&"0Q*(MBY)SN%? E0.Q(AD<"!X5*AQ >@[T=K.XZH$P$D0(NBD
MM<'YD#%--0-DE=YY28-*"T.=R=5V'EN1!AV\[C(%'/FN]>8)9(X^& 6$"Z7.\6):T^<71PR3;VV\[A(!B:'D"P[
M65:"[0%.%M/P?T89*L"NE M#L@G7=AX7?;3D26 1" 4W&$MKM*$!3 ?%< (P
M] M#GZG4=AX7E6B>M>@2#<)SKHAE@7,P]IPP#@N')T>E:*;_R8>9_P]K4PC4/K%N0;QU7>1$#Q(R"L*A9/@G/@#;G
M*CDKM$M!VRD0=R[F#32JSL?$ V)[;B1W@C*JO;%"ZH1=6CRAF$;)G>G0E@?%
M+*4D1I)/N_-6$6FD]* !M-9*+QYM)Q^*FSQ5L9!*V)#WL1*>K+6""VMI()&"
M(Y/"XE%U)D)QDR OI,-Q8VK*@63
MEBMCP>/1H#@I6!]6ATCSR8%46+$PU)E@*&Y,I(D&)S!E:') &H*EPY9JC97V
M$G-FU,*09DJAN'&125L>@D@8$\&M(%H:CG6Q[@ JCH?%(=/T0W%CJYZ4J-1!
M@OWAN G$&9^HE=F:I$Z.4AX7@623#L6-B3Y?,8F=XI!Q/T+";&I^J:&DN=>V=X"D9
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MYY$YYK#,&1(XPH1J.SDJ36L&<)3>GU+LG=^+F1;]E)[V :NL--DIO=;@?@'FQ;/R\[)0?MQI!([4'NR]?Y
M;T7;&W3CZJ@-^'C5P-65J^^YA?OY7FB=F=XQ'GE@V$2/8V0R:B<%I5VV+.CR<6V=WHV%O? .',V+
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M OPEGYU99_-1>E11&O$ARU?G>TX
M^-;3;O0ZP"MJ9?/#[E-<;1^(]CJ!7^5S1!T,:(XU]C$EDN;@H(BWC7;<2>O=
M&!K]+>O!N;UR=PO/>P]^@!$#KS7CQ=^V_;.UJ0>_-[/.7?XJWOBV8]MK[3!B
MJXNUHVZ,#PCE//C%]PWU:U0TOS2&W+@,%X&SP+SDAD2C.#:)V,2 'W&4HQ.KV-6)5?._*WJB
MQYRSAY],-::".&!>^^+H D\-#YI;12/-==X$,^#LTWDDZ'K3]GH[J:#936R!
M68F]?[]T7LP,T%10;G701&K*,3LU0L-V+_9L
M,W[[\MW&T7$?.@6O;K2/%I*3E*9.!2*)CMQH[$@*WA''N0XPXWH*G#07\Q;S
M03T2&Z)"X!1'&RE+0D7N/& J$?,D@;^\$& 7LDM'0M*,8T^<$AI3SJ@+ CS!
M*S@E\T#,V521#ZP#.$::>FF-BPE\IVS-@O\DN=9)$\6T\\S8D2=?DO)Q;NZ8
M2MD$'1.8H-I(D#B7-U)R90502UN'@P]W)6X& RYE;L.SQ'Q,R?XRA03"[65D
M,L?IM#?*Z!0H]0FDG&0QQVRFXR6=7F\=A@2Z-;8]2/3?%S7;'W1S$.7KSS"V$&.KV?*W7B[U>?N6+AFM![L<58."48NX9<8)P+IET0BC)G'&2.)ID
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MY.%?T 9M?G8G'5Y]\_&X>G+>JMYT93&]+2*L'H?8%TUU18K?R,
ME5RGW^^T5C* W6 N^ JLU+>N&:_N=YTNP"<"EFK:LUYT.<)'PU]I23)$]@&+^^&J^1%ZOBK0\W4_?'M-O&*<
M?O^U'K1KZB@O]H&9?%ST>]AI&G^?UKR6V=/7 F0T!E.8*/3NOD-O"
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M([__L+9;W]Q]>U#9W7RWLUNOO/NPN_=AK5:OU'-8^<^5
MG%6&AG(EML%\7QF_KKZ! "LA!U6AQ>-@+RZB[<;V?1 PVH8VC$O-)0 \6:F?
M5T^V/P4II1%)(F.E1IP(B4"0"4HLIWX3[!(!(=Z+9_VA!\?PK'VI71X0^,QJ&[56=>.40M\:!_5F
MHW:RR:NM;;+SK5%R7JWOPKUKK';R 3Y[7*4'7W;J!Y<[;_XYWMG?IM7ZT<7!
MR0=^URBQU.DDHD416X9X= IIY1(*FE!GO0S)^)%1PA?:**GOKM7VM@O3H[1*
M[K5*^E\E[,D8W7 !/+]L^*ZY5)_/BM/1
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MOO\^/R)]=T86 Z@>2.?M5[NO]EY5-EMGS]SR.AR( |